UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES
Investment Company Act file number 811-22883
ARK ETF Trust
(Exact name of registrant as specified in charter)
c/o ARK Investment Management LLC
155 West 19th Street, Fifth Floor
New York, NY 10011
(Address of principal executive offices) (Zip code)
Corporation Service Company
2711 Centerville Road
Suite 400
Wilmington, DE 19808
(Name and address of agent for service)
Registrant’s telephone number, including area code: (212) 426-7040
Date of fiscal year end: July 31
Date of reporting period: July 31, 2018
Form N-CSR is to be used by management investment companies to file reports with the Commission not later than 10 days after the transmission to stockholders of any report that is required to be transmitted to stockholders under Rule 30e-1 under the Investment Company Act of 1940 (17 CFR 270.30e-1). The Commission may use the information provided on Form N-CSR in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-CSR, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-CSR unless the Form displays a currently valid Office of Management and Budget ("OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.
Item 1. Reports to Stockholders.
The Report to Shareholders is attached herewith.
ARK ETF TRUST
ANNUAL REPORT
JULY 31, 2018
INVESTING AT THE PACE OF INNOVATION
ARK Genomic Revolution Multi-Sector ETF (ARKG)
ARK Industrial Innovation ETF (ARKQ)
ARK Innovation ETF (ARKK)
ARK Israel Innovative Technology ETF (IZRL)
ARK Web x.0 ETF (ARKW)
The 3D Printing ETF (PRNT)
ARK Invest | 155 West 19th Street 5th Floor, New York, NY 10011 | 212.426.7040 | info@ark-invest.com | ark-funds.com
TABLE OF CONTENTS
TABLE OF CONTENTS
The principal risks of investing in the ARK ETFs include: Equity Securities Risk: The value of the equity securities the Funds hold may fall due to general market and economic conditions. Foreign Securities Risk: Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities such as risks of currency exchange rates, differences in foreign accounting and legal standards, and government restrictions on repatriation of capital. Health Care Sector Risk: Companies in the health care sector may be adversely affected by government regulations and government health care programs. Industrials Sector Risk: Companies in the industrials sector may be adversely affected by changes in government regulation, world events, economic conditions, environmental damages, product liability claims and exchange rates. Information Technology Sector Risk: Information technology companies face intense competition, both domestically and internationally, which may have an adverse effect on profit margins. Cryptocurrency Investment Risks: The Funds may have exposure to cryptocurrency, such as bitcoin, indirectly through an investment in a grantor trust, The Bitcoin Investment Trust. The Funds’ exposure to cryptocurrencies may change over time and, accordingly, such exposure may not always be present in the Funds’ portfolios. Cryptocurrencies such as bitcoin are not “fiat” currencies of any central bank or government and currently are not subject to the authority of any central bank or government authority and are therefore not backed by any government. Even when exposure to cryptocurrency is indirect, such as through an investment trust, cryptocurrency may experience very high volatility and related investment vehicles such as the Bitcoin Investment Trust may be affected by such volatility. Funds having exposure to cryptocurrencies such as bitcoin may also trade from time to time at a significant premium to NAV. Tax Risk from investing in Bitcoin Investment Trust: The Bitcoin Investment Trust is a grantor trust for U.S. federal income tax purposes. As a result, the Bitcoin Investment Trust itself is not subject to U.S. federal income tax and as such, any income and expenses “flow through” to a Fund holding such investment, thus potentially generating income taxable to the Fund’s shareholders. Regulatory Risk of Investments in or having exposure to cryptocurrencies: Federal, state or foreign governments may restrict the use and exchange of cryptocurrencies such as bitcoin, and the approach by U.S. government agencies to the regulation of cryptocurrencies and the treatment of cryptocurrencies by courts under U.S. laws and regulations is still developing. Please see the ARK ETFs’ current prospectuses for more detailed descriptions of the risks of investing in the ARK ETFs.
The views expressed in the Shareholder Letter are those of ARK Investment Management LLC (“ARK”) as of July 31, 2018. Management’s Discussion of Fund Performance presents information about the ARK ETFs’ holdings that is believed to be accurate, and the views of the Funds’ portfolio manager, as of July 31, 2018. The Shareholder Letter and Management’s Discussion of Fund Performance may not necessarily reflect the views or holdings on the date this Annual Report is first published or anytime thereafter. The information in the Shareholder Letter and Management’s Discussion of Fund Performance may change, and the ARK ETFs disclaim any obligation to advise shareholders of any such changes. Certain information was obtained from sources that ARK believes to be reliable; however, ARK does not guarantee the accuracy or completeness of any information obtained from any third party.
Portfolio holdings will change and should not be considered as investment advice or a recommendation to buy, sell or hold any particular security. Please visit www.ark-funds.com for the most current list of portfolio holdings for the ARK ETFs.
The S&P 500 Index is a widely recognized capitalization-weighted index that measures the performance of the large-capitalization sector of the U.S. stock market. The MSCI World Index represents large and mid-cap equity performance across 23 developed markets countries. Returns shown for the MSCI World Index are net of foreign withholding taxes applicable to U.S. investors. Securities indexes assume reinvestment of all distributions and interest payments and do not take into account brokerage fees or taxes. Index performance information was furnished by sources deemed reliable and is believed to be accurate, however, no warranty or representation is made as to the accuracy thereof and the information is subject to correction. You cannot invest directly in an index, securities in an ARK ETF will not match those in an index, and performance of an ARK ETF will differ from the performance of an index. Although reinvestment of dividend and interest payments is assumed, no expenses are netted against an index’s returns.
TABLE OF CONTENTS
Shareholder Letter
(Unaudited)
Dear Shareholder:
This Annual Report for the ARK ETF Trust covers the period from August 1, 2017 through July 31, 2018 for each ARK exchange traded fund (“ETFs” or collectively, “ARK ETFs”). The ARK ETF Trust currently consists of four actively-managed, theme-based ETFs and two index-based ETFs:
 | | |
| ETF | | Commencement Date |
| ARK Genomic Revolution Multi-Sector ETF | | | 10/31/2014 | |
| ARK Industrial Innovation ETF | | | 09/30/2014 | |
| ARK Innovation ETF | | | 10/31/2014 | |
| ARK Israel Innovative Technology ETF | | | 12/05/2017 | |
| ARK Web x.0 ETF | | | 09/30/2014 | |
| The 3D Printing ETF | | | 07/19/2016 | |
ARK Investment Management LLC (“ARK”), the investment adviser to the ARK ETFs, specializes in thematic investing in disruptive innovation. ARK defines disruptive innovation as the introduction of a technologically enabled new product or service that should change an industry landscape by creating simplicity and accessibility while driving down costs. We believe innovation enables industry growth, facilitates convergence across different sectors of the economy, and drives long-term investment opportunities. Over time, innovation should displace industry incumbents, increase efficiencies, and gain majority market share.
Despite its potential, the full magnitude of disruptive innovation and the investment opportunities it creates are often unrecognized or misunderstood by traditional investors. ARK’s Research Ecosystem is designed to capture disruptive innovation through an open approach and the convergence of insights. A combination of top-down and bottom-up research allows us to identify disruptive innovation early, size the opportunity appropriately, and detect and rank companies best positioned to benefit. Our incisive investment process and active management of high-conviction portfolios allow us to capitalize on rapid change, and to avoid industries and companies likely to be displaced by advances in technology.
For this reason, ARK offers investment strategies focused solely on disruptive innovations centered around robotics/automation, energy storage, genomic sequencing, and next generation internet technologies, including deep learning, mobile connected devices, and blockchain technology.
On the following pages, you will find information relating to your ARK ETF investment. If you have any questions, I encourage you to contact your financial advisor or ARK directly. You also can find additional information, including our daily portfolio holdings, on the ARK ETF website located at: www.ark-funds.com.
We appreciate the opportunity to help you meet your investment goals and thank you for investing with us at the pace of innovation!
Sincerely,
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/sig_cathie-wood.jpg)
Catherine D. Wood
Chief Investment Officer and Chief Executive Officer
ARK Investment Management LLC
TABLE OF CONTENTS
Management’s Discussion of Fund Performance
(Unaudited)
Market Review and Investment Strategy
In the fiscal period ended July 31, 2018, equity markets around the world began to appreciate consistently despite concerns that the nine-year bull run has overstayed its welcome. Though the market could experience a correction at any time, our conviction in this bull market continues to strengthen.
The healthiest bull markets tend to climb walls of worry, with today’s bricks being cemented by concerns about a flattening yield curve in the US, trade tariffs, and geo-political concerns. While others argue that the yield curve is flagging signs of recession, we believe that it is discounting the early stages of a deflationary boom the likes of which has not been seen since the turn of the nineteenth century. During the next few years, we believe that real growth and profits around the world will surprise on the high side of expectations as inflation turns down and perhaps goes negative. Consequently, short rates are rising and will continue to rise in response to strong and accelerating real growth, while long rates will be tamed by continued surprises on the low side of inflation expectations. Strong growth also should push trade tensions to the back burner.
This explanation of the flattening yield curve seemingly suggests that “this time is different,” but this time is not different in the context of disruptive innovation. During the 50 years ended 1929, the last time multiple innovation platforms were evolving simultaneously, the yield curve was inverted more than half of the time.1 The disruptive innovations of that time — the internal combustion engine, telephone, and electricity – stimulated rapid real growth at low rates of inflation. Through booms and busts in an era without the Federal Reserve and with minimal government intervention, US real GDP growth averaged 3.7% and inflation 1.1%, while short-term rates averaged roughly 4.8% and long-term rates roughly 3.8%.2 The yield curve was inverted. So, this time is not different, but investors do have to extend their time horizons to understand the impact of profound technological breakthroughs on the economy.
ARK continues to research and discover companies that are causing or embracing disruptive innovation, spurring pockets of rapid growth in an otherwise sluggish growth environment. Relative to the S&P 500 Index and the MSCI World Index, ARK’s active ETFs outperformed during the fiscal period ended July 31, 2018, while ARK’s self-indexed ETFs underperformed.
During uncertain or tumultuous times, disruptive innovation tends to take root, enabling companies to cut costs, increase productivity, and create new products and services. At the same time, volatility tends to drive investment flows back to the more traditional benchmarks against which risk often is measured, and in which the majority of stocks associated with disruptive innovation are not well represented. ARK seeks to capitalize on opportunities missed as investors gravitate toward traditional benchmarks during uncertain times, while the fundamental growth associated with companies causing or embracing disruptive innovation accelerates.
| 1 | Gleaned from the figures and data pulled from Bloomberg |
| 2 | ARK Investment Management LLC, 2018; Data sourced from:
Bloomberg, http://socialdemocracy21stcentury.blogspot.com/2012/09/us-real-per-capita-gdp-from-18702001.html &
https://www.armstrongeconomics.com/us-population-1776-date/in combination were used to calculate the Real GDP Number; http://www.in2013dollars.com/inflation-rate-in-1929; http://www.multpl.com/10-year-treasury-rate/table/by-year |
TABLE OF CONTENTS
Management’s Discussion of Fund Performance (continued)
(Unaudited)
Investment Results: ARK Genomic Revolution Multi-Sector ETF (ARKG)
The ARK Genomic Revolution Multi-Sector ETF is an actively managed exchange traded fund that invests in companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
During the fiscal year ended July 31, 2018, the ARK Genomic Revolution Multi-Sector ETF (ARKG) outperformed the S&P 500 and the MSCI World Index.
The top contributors to ARKG’s performance were Juno Therapeutics (JUNO), Illumina (ILMN), Intellia Therapeutics (NTLA), Foundation Medicine (FMI), and Bluebird Bio (BLUE). Among the top contributors were stocks focused on immunotherapy, DNA sequencing, and genome-editing. In late 2017, the FDA approved the first two chimeric antigen t-cell (CAR-T) therapies, Novartis’ (NVS) Kymriah for pediatric acute lymphoblastic leukemia (ped-ALL) and Gilead’s (GILD) Yescarta for aggressive non-Hodgkin’s Lymphoma, a major victory for immunotherapy. Indeed, Juno Therapeutics (JUNO), the top contributor, was acquired by Celgene (CELG) at a 29% premium in January 2018. Juno is one of the leaders in CAR-T technology, a novel immunotherapy that promises a curative approach to treating metastatic cancers by harnessing an individual’s own immune system to fight malignant cells. Illumina (ILMN) also contributed to performance. DNA sequencing is the key enabler of the genomic revolution and Illumina has over 90% of all base pairs sequenced to date. We expect Illumina to continue to drive the costs of sequencing down with its improved instruments and chemistries. Intellia Therapeutics (NTLA), one of three public CRISPR genome-editing pure plays, was also a significant contributor to ARKG after securing two key CRISPR/Cas9 patents in the US and announcing its first cell therapy target for the treatment of acute myeloid leukemia. It also is paving the way to a safer drug delivery platform using non-bacterial vehicles.
The biggest detractors to ARKG’s performance were Seres Therapeutics (MCRB), Incyte Corporation (INCY), Syros Pharmaceuticals (SYRS), Organovo Holdings (ONVO), and Inovio Pharmaceuticals (INO). Among the detractors to the Fund, all are involved in early stage drug development focused on novel mechanisms of action. ARK believes that these companies are undervalued and possess a unique advantage over competitors focused on “me too” drugs. The Adviser broadly defines “me too” drugs as drugs that are structurally very similar to already known drugs, with only minor differences (i.e., generic drugs). Further, these companies are well-positioned to capitalize from intellectual property (IP). Seres Therapeutics (MCRB) is the leader in microbiome research and has a dedicated pipeline focused on reconstituting the gut microbiome to treat infectious diseases and improve cancer care outcomes. Incyte Corporation (INCY) is focused on identifying and developing biologics against novel drug targets across a number of disease settings. Lastly, Syros Pharmaceuticals (SYRS), a biopharmaceutical company focused on gene modulation, also detracted from the Fund’s performance. All three of these companies have been investing heavily in research and development (R&D) efforts at a time when the market seems less tolerant of research in novel mechanisms of action.
Average Annual Total Returns as of 7/31/18
| | | | | | | | | | | | | |
| | | 1 Year | | 3 Year | | Since Inception (Annualized) |
ARK Genomic Revolution Multi-Sector ETF (ARKG)
| |
| Net Asset Value | | | 33.80 | % | | | 9.47 | % | | | 11.17 | % |
| Market Price | | | 33.66 | % | | | 9.34 | % | | | 11.21 | % |
| S&P 500 Index | | | 16.24 | % | | | 12.52 | % | | | 11.91 | % |
| MSCI World Net Index | | | 11.88 | % | | | 8.95 | % | | | 8.77 | % |
Growth of an Assumed $10,000 Investment Since Inception* Through 7/31/18 (At Net Asset Value)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkg-line.jpg)
| * | ARKG’s inception date is 10/31/14. |
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. As stated in the ARK ETFs’ current prospectuses, the expense ratio for ARKG is 0.75%. Additional information about fees and expense levels can be found in the ARK ETFs’ current prospectuses. Net asset value (“NAV”) returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times.
The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares.
TABLE OF CONTENTS
Management’s Discussion of Fund Performance (continued)
(Unaudited)
Investment Results: ARK Industrial Innovation ETF (ARKQ)
The ARK Industrial Innovation ETF is an actively managed exchange traded fund that invests in securities of companies that are relevant to the Fund’s investment theme of industrial innovation.
During the fiscal year ended July 31, 2018 the ARK Industrial Innovation ETF (ARKQ) outperformed the S&P 500 and the MSCI World Index.
The top contributors to ARKQ’s performance were the Bitcoin Investment Trust (GBTC), Amazon (AMZN), Nvidia (NVDA), Align Technology (ALGN), and Aerovironment (AVAV). The top contributor was the Bitcoin Investment Trust (GBTC), which appreciated in December primarily as the result of significant speculation. In ARKQ, GBTC represents the promise of blockchain technology in supply chain management. Amazon (AMZN) also contributed as it continued its streak of outperformance because investors appreciate the leverage in its model, thanks to automated distribution centers, logistics-as-a-service, and growing cloud and advertising businesses. Nvidia (NVDA) also contributed over the course of the year as the importance of GPUs (Graphics Processing Unit) to deep learning and autonomous vehicles continued to grow.
Growth of an Assumed $10,000 Investment Since Inception* Through 7/31/18 (At Net Asset Value)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkq-line.jpg)
| * | ARKQ’s inception date is 9/30/14. |
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. As stated in the ARK ETFs’ current prospectuses, the expense ratio for ARKQ is 0.75%. Additional information about fees and expense levels can be found in the ARK ETFs’ current prospectuses. Net asset value (“NAV”) returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times.
The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares.
TABLE OF CONTENTS
Management’s Discussion of Fund Performance (continued)
(Unaudited)
Investment Results: ARK Innovation ETF (ARKK)
The ARK Innovation ETF is an actively managed exchange traded fund that invests in securities of companies that rely on or benefit from the development of new products or services, technological improvements and advancements in scientific research relating to the areas of genomics (“Genomic Revolution Theme”), industrial innovation (“Industrial Innovation Theme”) or the next generation internet (“Web x.0 Theme”).
During the fiscal year ended July 31, 2018, the ARK Innovation ETF outperformed the S&P 500 and the MSCI World Index.
The top contributors to ARKK’s performance were the Bitcoin Investment Trust (GBTC), Juno Therapeutics (JUNO), Twitter (TWTR), Illumina (ILMN), and Intellia Therapeutics (NTLA). Juno Therapeutics (JUNO) is one of the leaders in CAR-T technology, a novel immunotherapy that promises a curative approach to treating metastatic cancers by harnessing an individual’s own immune system to fight malignant cells. Celgene (CELG) bought Juno at a 29% premium in January 2018. Also boosting performance was a turn in sentiment towards Twitter (TWTR) as daily average users (DAUs) continued to grow at a double-digit rate, boosted by its use of artificial intelligence (AI) in personalizing timelines.
Growth of an Assumed $10,000 Investment Since Inception* Through 7/31/18 (At Net Asset Value)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkk-line.jpg)
| * | ARKK’s inception date is 10/31/14. |
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. As stated in the ARK ETFs’ current prospectuses, the expense ratio for ARKK is 0.75%. Additional information about fees and expense levels can be found in the ARK ETFs’ current prospectuses. Net asset value (“NAV”) returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times.
The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares.
TABLE OF CONTENTS
Management’s Discussion of Fund Performance (continued)
(Unaudited)
Investment Results: ARK Israel Innovative Technology ETF (IZRL)
The ARK Israel Innovative Technology ETF is an indexed exchange traded fund that seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the ARK Israeli Innovation Index, which is designed to track the price movements of exchange listed Israeli Companies whose main business operations are causing disruptive innovation in the areas of genomics, biotechnology, industrials, manufacturing, the Internet, and/or information technology.
Since inception (December 5, 2017), the ARK Israel Innovative Technology ETF (IZRL) has underperformed the S&P 500 Index and the MSCI World Index.
IZRL benefited from Redhill Biopharma (RDHL), Ceragon Networks (CRNT), Wix.com (WIX), Solaredge Technologies (SEDG), and Teva Pharmaceutical Industries (TEVA). Wix.com (WIX), pioneering the use of machine learning for automated
webpage design, benefitted from better than expected revenue growth of 41% in the second quarter of 2017.
Detracting from IZRL’s performance were Vascular Biogenics (VBLT), Cellcom (CEL IT), Tower Semiconductor (TSEM), Aeronautics (ARCS IT), and Partner Communications (PTNR IT). Cellcom (CEL IT) detracted because of declining service revenue and profitability due to increased competition.
Average Annual Total Returns as of 7/31/18
| | | | | |
| | | Since Inception |
ARK Israel Innovative Technology ETF (IZRL)
| |
| Net Asset Value | | | 4.27 | % |
| Market Price | | | 5.20 | % |
| S&P 500 Index | | | 7.97 | % |
| MSCI World Net Index | | | 5.34 | % |
Growth of an Assumed $10,000 Investment Since Inception* Through 7/31/18 (At Net Asset Value)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_izrl-line.jpg)
| * | IZRL’s inception date is 12/5/17. |
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. As stated in the ARK ETFs’ current prospectuses, the expense ratio for IZRL is 0.49%. Additional information about fees and expense levels can be found in the ARK ETFs’ current prospectuses. Net asset value (“NAV”) returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times.
The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares. Returns for less than one year are not annualized.
TABLE OF CONTENTS
Management’s Discussion of Fund Performance (continued)
(Unaudited)
Investment Results: ARK Web x.0 ETF (ARKW)
The ARK Web x.0 ETF is an actively managed exchange traded fund that invests in securities of companies that are relevant to the Fund’s investment theme of Web x.0, or the next generation internet.
During the fiscal year ended July 31, 2018, the ARK Web x.0 ETF (ARKW) outperformed both the S&P 500 Index and the MSCI World Index.
The top contributors to ARKW’s performance were the Bitcoin Investment Trust (GBTC), Twitter (TWTR), Amazon (AMZN), Square (SQ), and Netflix (NFLX). Twitter (TWTR) benefited from a turn in sentiment as daily average users (DAUs) continued to grow at a double-digit rate, boosted by its use of artificial intelligence (AI) in personalizing timelines. Amazon (AMZN) also contributed, benefiting from its dominance of online retail during the holiday season and Amazon Web Services which has reached a new milestone of $24 billion in annualized revenue run rate. Square (SQ) responded strongly to the accelerated growth of its ecosystem and its “Cash App”. The company is continuing to build its ecosystem into a one-stop platform and in the process, is becoming more valuable to its customers. Square Cash, which has extended features like bitcoin purchasing functionality, is establishing a strategic position as a crypto wallet provider.
Growth of an Assumed $10,000 Investment Since Inception* Through 7/31/18 (At Net Asset Value)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkw-line.jpg)
| * | ARKW’s inception date is 9/30/14. |
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. As stated in the ARK ETFs’ current prospectuses, the expense ratio for ARKW is 0.75%. Additional information about fees and expense levels can be found in the ARK ETFs’ current prospectuses. Net asset value (“NAV”) returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times.
The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares.
TABLE OF CONTENTS
Management’s Discussion of Fund Performance (concluded)
(Unaudited)
Investment Results: The 3D Printing ETF (PRNT)
The 3D Printing ETF is an indexed exchange traded fund that seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Total 3D-Printing Index, which is designed to track the price movements of the stocks of companies involved in the 3D printing industry.
The 3D Printing ETF is the only pure-play ETF dedicated to the 3D printing ecosystem. During the fiscal year ended July 31, 2018, The 3D Printing ETF (PRNT) underperformed the S&P 500 Index and the MSCI World Index.
The top contributors to PRNT’s performance were Exa Corporation (EXA), Dassault Systems (DSY FP), PTC Inc. (PTC), Renishaw (RSW LN), and Microsoft (MSFT). Dassault Systems (DSY), a provider of computer aided design software used for 3D printing, and Exa Corporation (EXA), a simulation software company, benefited as Dassault bought Exa. Dassault believes that Exa’s fluid simulation tools complement its multi-physics design and simulation suite across industries.
Growth of an Assumed $10,000 Investment Since Inception* Through 7/31/18 (At Net Asset Value)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_prnt-line.jpg)
| * | PRNT’s inception date is 7/19/16. |
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. As stated in the ARK ETFs’ current prospectuses, the expense ratio for PRNT is 0.66%. Additional information about fees and expense levels can be found in the ARK ETFs’ current prospectuses. Net asset value (“NAV”) returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times.
The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares.
TABLE OF CONTENTS
Shareholder Expense Examples
(Unaudited)
As a shareholder of an ARK ETF (each, a “Fund” and collectively, “Funds”) you incur two types of costs: (1) transaction costs for purchasing and selling shares; and (2) ongoing costs, including management fees and other Fund expenses. The following examples are intended to help you understand your ongoing costs (in dollars and cents) of investing in the Funds and to compare these costs with the ongoing costs of investing in other funds.
The examples below are based on an investment of $1,000 invested at the beginning of the six-month period and held for the entire period (February 1, 2018 through July 31, 2018).
Actual Expenses
The first line under each Fund in the table below provides information about actual account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line for your Fund under the heading entitled “Expenses Paid During the Period” to estimate the expenses you paid on your account during the period.
Hypothetical Example for Comparison Purposes
The second line under each Fund in the table below provides information about hypothetical account values and hypothetical expenses based on each Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate your actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund to other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.
Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales of Fund shares. Therefore, the second line under each Fund in the table is useful in comparing ongoing Fund costs only and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.
| | | | | | | | |
| | | Beginning Account Value 2/1/2018 | | Ending
Account Value 7/31/2018 | | Annualized Expense Ratios for the Period | | Expenses Paid During the
Period(a) |
ARK Genomic Revolution Multi-Sector ETF
| | | | | | | | | | | | | | | | |
| Actual | | $ | 1,000.00 | | | $ | 1,061.40 | | | | 0.75 | % | | $ | 3.83 | |
| Hypothetical (5% return before expenses) | | $ | 1,000.00 | | | $ | 1,021.08 | | | | 0.75 | % | | $ | 3.76 | |
ARK Industrial Innovation ETF
| | | | | | | | | | | | | | | | |
| Actual | | $ | 1,000.00 | | | $ | 969.90 | | | | 0.75 | % | | $ | 3.66 | |
| Hypothetical (5% return before expenses) | | $ | 1,000.00 | | | $ | 1,021.08 | | | | 0.75 | % | | $ | 3.76 | |
ARK Innovation ETF
| | | | | | | | | | | | | | | | |
| Actual | | $ | 1,000.00 | | | $ | 1,082.60 | | | | 0.75 | % | | $ | 3.87 | |
| Hypothetical (5% return before expenses) | | $ | 1,000.00 | | | $ | 1,021.08 | | | | 0.75 | % | | $ | 3.76 | |
ARK Israel Innovative Technology ETF
| | | | | | | | | | | | | | | | |
| Actual | | $ | 1,000.00 | | | $ | 986.90 | | | | 0.49 | % | | $ | 2.41 | |
| Hypothetical (5% return before expenses) | | $ | 1,000.00 | | | $ | 1,022.36 | | | | 0.49 | % | | $ | 2.46 | |
ARK Web x.0 ETF
| | | | | | | | | | | | | | | | |
| Actual | | $ | 1,000.00 | | | $ | 1,088.70 | | | | 0.75 | % | | $ | 3.88 | |
| Hypothetical (5% return before expenses) | | $ | 1,000.00 | | | $ | 1,021.08 | | | | 0.75 | % | | $ | 3.76 | |
The 3D Printing ETF
| | | | | | | | | | | | | | | | |
| Actual | | $ | 1,000.00 | | | $ | 936.40 | | | | 0.66 | % | | $ | 3.17 | |
| Hypothetical (5% return before expenses) | | $ | 1,000.00 | | | $ | 1,021.52 | | | | 0.66 | % | | $ | 3.31 | |
| (a) | Expenses are equal to each Fund’s annualized expense ratio, multiplied by the average account value over the period, multiplied by 181/365 (the number of days in the period, then divided by 365.) |
TABLE OF CONTENTS
Sector Diversification (as a percentage of total investments)
July 31, 2018 (Unaudited)
ARK Genomic Revolution
Multi-Sector ETF (ARKG)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkg-pie.jpg)
| | |
< Health Care | | | 95.8 | % |
< Information Technology | | | 3.9 | |
< Money Market Fund | | | 0.3 | |
| | | | 100.0 | |
ARK Industrial Innovation ETF (ARKQ)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkq-pie.jpg)
| | |
< Information Technology | | | 53.8 | % |
< Consumer Discretionary | | | 28.8 | |
< Industrials | | | 9.6 | |
< Health Care | | | 7.4 | |
< Money Market Fund | | | 0.2 | |
< Financials | | | 0.2 | |
| | | | 100.0 | |
ARK Innovation ETF (ARKK)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkk-pie.jpg)
| | |
< Information Technology | | | 41.4 | % |
< Health Care | | | 35.1 | |
< Consumer Discretionary | | | 17.2 | |
< Financials | | | 4.0 | |
< Real Estate | | | 1.4 | |
< Industrials | | | 0.5 | |
< Money Market Fund | | | 0.4 | |
| | | | 100.0 | |
ARK Israel Innovative Technology ETF (IZRL)
| | |
< Information Technology | | | 58.3 | % |
< Health Care | | | 25.0 | |
< Telecommunication Services | | | 9.6 | |
< Industrials | | | 7.0 | |
< Money Market Fund | | | 0.1 | |
| | | | 100.0 | |
ARK Web x.0 ETF (ARKW)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_arkw-pie.jpg)
| | |
< Information Technology | | | 65.9 | % |
< Consumer Discretionary | | | 17.3 | |
< Health Care | | | 8.0 | |
< Financials | | | 5.6 | |
< Telecommunication Services | | | 1.7 | |
< Real Estate | | | 1.2 | |
< Money Market Fund | | | 0.3 | |
| | | | 100.0 | |
The 3D Printing ETF (PRNT)
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/tv501825_prnt-pie.jpg)
| | |
< Information Technology | | | 57.7 | % |
< Industrials | | | 30.3 | |
< Health Care | | | 10.1 | |
< Materials | | | 1.4 | |
< Money Market Fund | | | 0.4 | |
< Consumer Staples | | | 0.1 | |
| | | | 100.0 | |
TABLE OF CONTENTS
Schedule of Investments
ARK Genomic Revolution Multi-Sector ETF
July 31, 2018
| | | | |
| Investments | | Shares | | Value |
COMMON STOCKS — 99.7%
| | | | | | | | |
Biotechnology — 69.0%
| |
| AquaBounty Technologies, Inc.* | | | 192,621 | | | $ | 548,970 | |
| Arcturus Therapeutics Ltd.*† | | | 602,348 | | | | 4,728,432 | |
| BeiGene Ltd. (China)*(a) | | | 12,250 | | | | 2,323,335 | |
| Bellicum Pharmaceuticals, Inc.* | | | 459,442 | | | | 2,922,051 | |
| Biogen, Inc.* | | | 17,548 | | | | 5,867,525 | |
| Bluebird Bio, Inc.* | | | 62,035 | | | | 9,609,221 | |
| Celgene Corp.* | | | 115,174 | | | | 10,376,026 | |
| Cellectis SA (France)*(a) | | | 283,218 | | | | 8,185,000 | |
| CRISPR Therapeutics AG (Switzerland)* | | | 169,431 | | | | 8,088,636 | |
| Editas Medicine, Inc.* | | | 471,887 | | | | 14,033,919 | |
| Evelo Biosciences, Inc.* | | | 184,259 | | | | 2,329,034 | |
| Evogene Ltd. (Israel)* | | | 188,839 | | | | 543,856 | |
| Incyte Corp.* | | | 49,558 | | | | 3,297,589 | |
| Inovio Pharmaceuticals, Inc.* | | | 1,453,475 | | | | 5,828,435 | |
| Intellia Therapeutics, Inc.* | | | 930,710 | | | | 24,775,500 | |
| Invitae Corp.* | | | 1,787,466 | | | | 15,801,199 | |
| Ionis Pharmaceuticals, Inc.* | | | 115,496 | | | | 5,044,865 | |
| Iovance Biotherapeutics, Inc.* | | | 174,349 | | | | 2,475,756 | |
| Organovo Holdings, Inc.* | | | 3,148,564 | | | | 3,746,791 | |
| Pluristem Therapeutics, Inc.* | | | 1,918,154 | | | | 2,397,693 | |
| Regeneron Pharmaceuticals, Inc.* | | | 22,880 | | | | 8,420,069 | |
| Seres Therapeutics, Inc.* | | | 763,426 | | | | 5,779,135 | |
| Syros Pharmaceuticals, Inc.* | | | 422,538 | | | | 4,276,085 | |
| Veracyte, Inc.* | | | 817,811 | | | | 8,856,893 | |
| Total Biotechnology | | | | | | | 160,256,015 | |
Health Care Equipment & Supplies — 2.0%
| |
| Cerus Corp.* | | | 622,150 | | | | 4,610,131 | |
| | | | | | | | | |
| | | | |
| Investments | | Shares | | Value |
Health Care Technology — 5.6%
| |
| athenahealth, Inc.* | | | 34,134 | | | $ | 5,144,335 | |
| Medidata Solutions, Inc.* | | | 105,117 | | | | 7,811,244 | |
| Total Health Care Technology | | | | | | | 12,955,579 | |
Life Sciences Tools & Services — 18.1%
| |
| Compugen Ltd. (Israel)* | | | 1,768,583 | | | | 5,571,037 | |
| Illumina, Inc.* | | | 59,770 | | | | 19,386,997 | |
| NanoString Technologies, Inc.* | | | 594,837 | | | | 6,977,438 | |
| Pacific Biosciences of California, Inc.* | | | 2,682,945 | | | | 10,195,191 | |
| Total Life Sciences Tools & Services | | | | | | | 42,130,663 | |
Pharmaceuticals — 1.1%
| |
| Bristol-Myers Squibb Co. | | | 43,043 | | | | 2,528,776 | |
Semiconductors & Semiconductor Equipment — 1.1%
| |
| NVIDIA Corp. | | | 10,085 | | | | 2,469,413 | |
Technology Hardware, Storage & Peripherals — 2.8%
| |
| Apple, Inc. | | | 34,254 | | | | 6,518,194 | |
Total Common Stocks
(Cost $211,928,818) | | | | | | | 231,468,771 | |
MONEY MARKET FUND — 0.3%
| |
Morgan Stanley Institutional Liquidity Fund — Government
Portfolio, 1.81%(b) (Cost $632,819) | | | 632,819 | | | | 632,819 | |
Total Investments — 100.0%
(Cost $212,561,637) | | | | | | | 232,101,590 | |
| Other Assets in Excess of Liabilities — 0.0%†† | | | 13,388 | |
| Net Assets – 100.0% | | | | | | | $232,114,978 | |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments (continued)
ARK Genomic Revolution Multi-Sector ETF
July 31, 2018
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
| • | Level 1 — Quoted prices in active markets for identical assets. |
| • | Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| • | Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of July 31, 2018, based upon the three levels defined above:
| | | | | | | | |
| ARK Genomic Revolution Multi-Sector ETF | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets
| | | | | | | | | | | | | | | | |
| Common Stocks* | | $ | 231,468,771 | | | $ | — | | | $ | — | | | $ | 231,468,771 | |
| Money Market Fund | | | 632,819 | | | | — | | | | — | | | | 632,819 | |
| Total | | $ | 232,101,590 | | | $ | — | | | $ | — | | | $ | 232,101,590 | |
| * | Please refer to the Schedule of Investments to view securities segregated by industry type. |
There were no Level 2 or 3 investments held in the Fund as of July 31, 2018.
The Fund’s policy is to recognize transfers between levels at the beginning of the period. There were no transfers between levels for the year ended July 31, 2018, based on levels assigned to securities as of July 31, 2017.
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments
ARK Industrial Innovation ETF
July 31, 2018
| | | | |
| Investments | | Shares | | Value |
COMMON STOCKS — 99.6%
| | | | | | | | |
Aerospace & Defense — 3.9%
| |
| Aerovironment, Inc.* | | | 58,902 | | | $ | 4,335,776 | |
| Elbit Systems Ltd. (Israel) | | | 13,635 | | | | 1,640,563 | |
| Total Aerospace & Defense | | | | | | | 5,976,339 | |
Auto Components — 4.7%
| |
| Aptiv PLC | | | 74,888 | | | | 7,344,266 | |
Automobiles — 15.1%
| |
| Daimler AG (Germany)(a) | | | 117,051 | | | | 2,017,374 | |
| General Motors Co. | | | 90,811 | | | | 3,442,645 | |
| Tesla, Inc.* | | | 55,191 | | | | 16,454,645 | |
| Toyota Motor Corp. (Japan)(a) | | | 11,932 | | | | 1,573,115 | |
| Total Automobiles | | | | | | | 23,487,779 | |
Biotechnology — 1.2%
| |
| Organovo Holdings, Inc.* | | | 1,603,925 | | | | 1,908,671 | |
Electrical Equipment — 1.1%
| |
| Rockwell Automation, Inc. | | | 9,134 | | | | 1,713,173 | |
Electronic Equipment, Instruments & Components — 4.3%
| |
| Cognex Corp. | | | 52,106 | | | | 2,750,155 | |
| Trimble, Inc.* | | | 112,553 | | | | 3,973,121 | |
| Total Electronic Equipment, Instruments & Components | | | | | | | 6,723,276 | |
Health Care Equipment & Supplies — 6.2%
| |
| Align Technology, Inc.* | | | 12,085 | | | | 4,310,115 | |
| Intuitive Surgical, Inc.* | | | 3,377 | | | | 1,716,158 | |
| Mazor Robotics Ltd. (Israel)*(a) | | | 57,884 | | | | 3,624,696 | |
| Total Health Care Equipment & Supplies | | | | | | | 9,650,969 | |
Internet & Direct Marketing Retail — 9.0%
| |
| Amazon.com, Inc.* | | | 3,477 | | | | 6,180,159 | |
| JD.com, Inc. (China)*(a) | | | 169,922 | | | | 6,093,403 | |
| Rakuten, Inc. (Japan)(a) | | | 232,893 | | | | 1,647,718 | |
| Total Internet & Direct Marketing Retail | | | | | | | 13,921,280 | |
Internet Software & Services — 15.0%
| |
| 2U, Inc.* | | | 14,032 | | | | 1,061,661 | |
| Alphabet, Inc., Class C* | | | 4,708 | | | | 5,730,860 | |
| Baidu, Inc. (China)*(a) | | | 48,151 | | | | 11,901,964 | |
| Cornerstone OnDemand, Inc.* | | | 31,092 | | | | 1,535,945 | |
| Tencent Holdings Ltd. (China)(a) | | | 65,620 | | | | 2,998,834 | |
| Total Internet Software & Services | | | | | | | 23,229,264 | |
Machinery — 4.6%
| |
| Deere & Co. | | | 14,884 | | | | 2,155,054 | |
| ExOne Co. (The)* | | | 225,930 | | | | 1,563,436 | |
| Proto Labs, Inc.* | | | 27,415 | | | | 3,417,280 | |
| Total Machinery | | | | | | | 7,135,770 | |
| | | | |
| Investments | | Shares | | Value |
Semiconductors & Semiconductor Equipment — 14.6%
| |
| Infineon Technologies AG (Germany)(a) | | | 640 | | | $ | 16,976 | |
| NVIDIA Corp. | | | 27,240 | | | | 6,669,986 | |
| NXP Semiconductors NV (Netherlands)* | | | 25,938 | | | | 2,472,929 | |
Taiwan Semiconductor Manufacturing Co. Ltd.
(Taiwan)(a) | | | 42,858 | | | | 1,766,178 | |
| Teradyne, Inc. | | | 175,033 | | | | 7,570,177 | |
| Xilinx, Inc. | | | 59,154 | | | | 4,263,229 | |
| Total Semiconductors & Semiconductor Equipment | | | | | | | 22,759,475 | |
Software — 8.0%
| |
| ANSYS, Inc.* | | | 9,722 | | | | 1,641,852 | |
| Autodesk, Inc.* | | | 20,448 | | | | 2,626,341 | |
| Materialise NV (Belgium)*(a) | | | 437,302 | | | | 5,505,632 | |
| Splunk, Inc.* | | | 28,110 | | | | 2,701,371 | |
| Total Software | | | | | | | 12,475,196 | |
Technology Hardware, Storage & Peripherals — 11.9%
| |
| Apple, Inc. | | | 8,482 | | | | 1,614,040 | |
| Nano Dimension Ltd. (Israel)*(a) | | | 443,341 | | | | 899,982 | |
| Stratasys Ltd.* | | | 824,937 | | | | 16,020,276 | |
| Total Technology Hardware, Storage & Peripherals | | | | | | | 18,534,298 | |
Total Common Stocks
(Cost $139,058,548) | | | | | | | 154,859,756 | |
UNIT TRUST — 0.2%
| |
Financials — 0.2%
| | | | | | | | |
Bitcoin Investment Trust
(Cost $88,583) | | | 20,193 | | | | 210,411 | |
MONEY MARKET FUND — 0.2%
| |
| Morgan Stanley Institutional Liquidity Fund — Government Portfolio, 1.81%(b) (Cost $376,699) | | | 376,699 | | | | 376,699 | |
Total Investments — 100.0%
(Cost $139,523,830) | | | | | | | 155,446,866 | |
| Other Assets in Excess of Liabilities — 0.0%† | | | 647 | |
| Net Assets — 100.0% | | | | | | | $155,447,513 | |
| | |
| * | | Non-income producing security |
| † | | Less than 0.05% |
| (a) | | American Depositary Receipt |
| (b) | | Rate shown represents annualized 7-day yield as of July 31, 2018. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments (continued)
ARK Industrial Innovation ETF
July 31, 2018
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
| • | Level 1 — Quoted prices in active markets for identical assets. |
| • | Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| • | Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of July 31, 2018, based upon the three levels defined above:
| | | | | | | | |
| ARK Industrial Innovation ETF | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets
| | | | | | | | | | | | | | | | |
| Common Stocks* | | $ | 154,859,756 | | | $ | — | | | $ | — | | | $ | 154,859,756 | |
| Unit Trust* | | | 210,411 | | | | — | | | | — | | | | 210,411 | |
| Money Market Fund | | | 376,699 | | | | — | | | | — | | | | 376,699 | |
| Total | | $ | 155,446,866 | | | $ | — | | | $ | — | | | $ | 155,446,866 | |
| * | Please refer to the Schedule of Investments to view securities segregated by industry type. |
There were no Level 2 or 3 investments held in the Fund as of July 31, 2018.
The Fund’s policy is to recognize transfers between levels at the beginning of the period. There were no transfers between levels for the year ended July 31, 2018, based on levels assigned to securities as of July 31, 2017.
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments
ARK Innovation ETF
July 31, 2018
| | | | |
| Investments | | Shares | | Value |
COMMON STOCKS — 99.5%
| | | | | | | | |
Auto Components — 2.4%
| |
| Aptiv PLC | | | 284,213 | | | $ | 27,872,769 | |
Automobiles — 8.0%
| |
| Tesla, Inc.* | | | 312,484 | | | | 93,163,980 | |
Biotechnology — 21.9%
| |
| Bluebird Bio, Inc.* | | | 147,221 | | | | 22,804,533 | |
| CRISPR Therapeutics AG (Switzerland)* | | | 297,684 | | | | 14,211,434 | |
| Editas Medicine, Inc.* | | | 1,223,327 | | | | 36,381,745 | |
| Intellia Therapeutics, Inc.*† | | | 2,929,584 | | | | 77,985,526 | |
| Invitae Corp.*† | | | 5,505,238 | | | | 48,666,304 | |
| Organovo Holdings, Inc.*† | | | 8,452,504 | | | | 10,058,480 | |
| Seres Therapeutics, Inc.* | | | 1,964,342 | | | | 14,870,069 | |
| Syros Pharmaceuticals, Inc.* | | | 1,227,209 | | | | 12,419,355 | |
| Veracyte, Inc.* | | | 1,712,396 | | | | 18,545,249 | |
| Total Biotechnology | | | | | | | 255,942,695 | |
Consumer Finance — 2.6%
| |
| LendingClub Corp.* | | | 7,522,125 | | | | 30,991,155 | |
Health Care Equipment & Supplies — 2.3%
| |
| Cerus Corp.* | | | 3,662,954 | | | | 27,142,489 | |
Health Care Technology — 2.0%
| |
| Medidata Solutions, Inc.* | | | 320,755 | | | | 23,835,304 | |
Internet & Direct Marketing Retail — 6.8%
| |
| Amazon.com, Inc.* | | | 14,493 | | | | 25,760,438 | |
| JD.com, Inc. (China)*(a) | | | 787,064 | | | | 28,224,115 | |
| Netflix, Inc.* | | | 77,156 | | | | 26,036,292 | |
| Total Internet & Direct Marketing Retail | | | | | | | 80,020,845 | |
Internet Software & Services — 13.7%
| |
| Alibaba Group Holding Ltd. (China)*(a) | | | 71,609 | | | | 13,407,353 | |
| Baidu, Inc. (China)*(a) | | | 160,113 | | | | 39,576,731 | |
| MercadoLibre, Inc. (Argentina) | | | 35,149 | | | | 12,052,944 | |
| Spotify Technology SA* | | | 136,617 | | | | 24,977,686 | |
| Tencent Holdings Ltd. (China)(a) | | | 461,334 | | | | 21,082,964 | |
| Twitter, Inc.* | | | 1,554,636 | | | | 49,546,249 | |
| Total Internet Software & Services | | | | | | | 160,643,927 | |
IT Services — 3.0%
| |
| Square, Inc., Class A* | | | 538,654 | | | | 34,823,981 | |
Life Sciences Tools & Services — 8.9%
| |
| Compugen Ltd. (Israel)*† | | | 3,738,007 | | | | 11,774,722 | |
| Illumina, Inc.* | | | 150,777 | | | | 48,906,028 | |
| NanoString Technologies, Inc.*† | | | 2,396,663 | | | | 28,112,857 | |
| Pacific Biosciences of California, Inc.* | | | 4,073,792 | | | | 15,480,409 | |
| Total Life Sciences Tools & Services | | | | | | | 104,274,016 | |
| | | | |
| Investments | | Shares | | Value |
Machinery — 0.5%
| |
| ExOne Co. (The)*† | | | 875,090 | | | $ | 6,055,623 | |
Real Estate Management & Development — 1.4%
| |
| Redfin Corp.* | | | 674,189 | | | | 16,517,631 | |
Semiconductors & Semiconductor Equipment — 9.9%
| |
| NVIDIA Corp. | | | 105,532 | | | | 25,840,565 | |
Taiwan Semiconductor Manufacturing Co. Ltd.
(Taiwan)(a) | | | 620,515 | | | | 25,571,423 | |
| Teradyne, Inc. | | | 853,287 | | | | 36,904,663 | |
| Xilinx, Inc. | | | 375,709 | | | | 27,077,348 | |
| Total Semiconductors & Semiconductor Equipment | | | | | | | 115,393,999 | |
Software — 6.3%
| |
| Materialise NV (Belgium)*(a) | | | 1,460,576 | | | | 18,388,652 | |
| MGT Capital Investments, Inc.* | | | 2,091,019 | | | | 1,651,905 | |
| Microsoft Corp. | | | 422 | | | | 44,766 | |
| Red Hat, Inc.* | | | 146,686 | | | | 20,716,464 | |
| salesforce.com, Inc.* | | | 121,106 | | | | 16,609,688 | |
| Splunk, Inc.* | | | 168,253 | | | | 16,169,113 | |
| Total Software | | | | | | | 73,580,588 | |
Technology Hardware, Storage & Peripherals — 8.7%
| |
| Apple, Inc. | | | 106,212 | | | | 20,211,081 | |
| Stratasys Ltd.*† | | | 4,193,404 | | | | 81,435,905 | |
| Total Technology Hardware, Storage & Peripherals | | | | | | | 101,646,986 | |
Thrifts & Mortgage Finance — 1.1%
| |
| LendingTree, Inc.* | | | 51,560 | | | | 12,312,528 | |
Total Common Stocks
(Cost $1,085,258,681) | | | | | | | 1,164,218,516 | |
UNIT TRUST — 0.2%
| |
Financials — 0.2%
| | | | | | | | |
Bitcoin Investment Trust
(Cost $1,333,126) | | | 305,896 | | | | 3,187,437 | |
MONEY MARKET FUND — 0.4%
| |
| Morgan Stanley Institutional Liquidity Fund — Government Portfolio, 1.81%(b) (Cost $4,117,527) | | | 4,117,527 | | | | 4,117,527 | |
Total Investments — 100.1%
(Cost $1,090,709,334) | | | | | | | 1,171,523,480 | |
| Liabilities in Excess of Other Assets — (0.1)% | | | (935,295 | ) |
| Net Assets — 100.0% | | | | | | | $1,170,588,185 | |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments (continued)
ARK Innovation ETF
July 31, 2018
Affiliated Issuer Transactions
A summary of the Fund’s transactions with affiliated investments during the year ended July 31, 2018 is as follows:
| | | | | | | | | | | | | | | | |
| Value ($) at 7/31/2017 | | Purchases Cost
($) | | Sales Proceeds
($) | | Net Realized Gain/(Loss) ($) | | Net Change in Unrealized Appreciation (Depreciation) ($) | | Dividend
Income
($) | | Capital Gain Distributions ($) | | Number of
Shares at
7/31/2018 | | Value ($) at
7/31/2018 |
Common Stocks — 22.6%
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Machinery — 0.5%
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ExOne Co. (The)† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1,055,841 | | | 9,211,946 | | | | (1,839,988 | ) | | | (991,022 | ) | | | (1,381,154 | ) | | | — | | | | — | | | | 875,090 | | | | 6,055,623 | |
Biotechnology — 11.7%
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Intellia Therapeutics, Inc.† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2,021,187 | | | 86,449,167 | | | | (18,183,768 | ) | | | 257,859 | | | | 7,441,081 | | | | — | | | | — | | | | 2,929,584 | | | | 77,985,526 | |
| Invitae Corp.† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1,643,284 | | | 40,870,950 | | | | (2,261,872 | ) | | | (69,202 | ) | | | 8,483,144 | | | | — | | | | — | | | | 5,505,238 | | | | 48,666,304 | |
| Organovo Holdings, Inc.† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 784,249 | | | 12,198,867 | | | | (587,835 | ) | | | 25,209 | | | | (2,362,010 | ) | | | — | | | | — | | | | 8,452,504 | | | | 10,058,480 | |
Life Sciences Tools & Services — 3.4%
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Compugen Ltd.† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1,188,918 | | | 12,022,409 | | | | (769,337 | ) | | | 208,557 | | | | (875,825 | ) | | | — | | | | — | | | | 3,738,007 | | | | 11,774,722 | |
| NanoString Technologies, Inc.† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1,146,012 | | | 26,535,412 | | | | (3,319,019 | ) | | | (1,094,484 | ) | | | 4,844,936 | | | | — | | | | — | | | | 2,396,663 | | | | 28,112,857 | |
Technology Hardware, Storage & Peripherals — 7.0%
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Stratasys Ltd.† | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3,823,023 | | | 88,816,526 | | | | (6,201,145 | ) | | | (358,688 | ) | | | (4,643,811 | ) | | | — | | | | — | | | | 4,193,404 | | | | 81,435,905 | |
| 11,662,514 | | | 276,105,277 | | | | (33,162,964 | ) | | | (2,021,771 | ) | | | 11,506,361 | | | | — | | | | — | | | | 28,090,490 | | | | 264,089,417 | |
| | |
| * | | Non-income producing security |
| † | | Affiliated security |
| (a) | | American Depositary Receipt |
| (b) | | Rate shown represents annualized 7-day yield as of July 31, 2018. |
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
| • | Level 1 — Quoted prices in active markets for identical assets. |
| • | Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| • | Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of July 31, 2018, based upon the three levels defined above:
| | | | | | | | |
| ARK Innovation ETF | | Level 1 | | Level 2 | | Level 3 | | Total |
| Assets | | | | | | | | | | | | | | | | |
| Common Stocks* | | $ | 1,164,218,516 | | | $ | — | | | $ | — | | | $ | 1,164,218,516 | |
| Unit Trust* | | | 3,187,437 | | | | — | | | | — | | | | 3,187,437 | |
| Money Market Fund | | | 4,117,527 | | | | — | | | | — | | | | 4,117,527 | |
| Total | | $ | 1,171,523,480 | | | $ | — | | | $ | — | | | $ | 1,171,523,480 | |
| * | Please refer to the Schedule of Investments to view securities segregated by industry type. |
There were no Level 2 or 3 investments held in the Fund as of July 31, 2018.
The Fund’s policy is to recognize transfers between levels at the beginning of the year. There were no transfers between levels for the year ended July 31, 2018, based on levels assigned to securities as of July 31, 2017.
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments
ARK Israel Innovative Technology ETF
July 31, 2018
| | | | |
| Investments | | Shares | | Value |
COMMON STOCKS — 99.9%
| | | | | | | | |
Aerospace & Defense — 2.4%
| | | | | | | | |
| Elbit Systems Ltd. (Israel) | | | 4,409 | | | $ | 528,283 | |
Biotechnology — 11.2%
| |
Galmed Pharmaceuticals Ltd.
(Israel)* | | | 35,012 | | | | 475,463 | |
| Intec Pharma Ltd. (Israel)* | | | 105,123 | | | | 436,261 | |
| Kamada Ltd. (Israel)* | | | 95,175 | | | | 536,756 | |
| Pluristem Therapeutics, Inc.* | | | 418,513 | | | | 514,109 | |
| UroGen Pharma Ltd. (Israel)* | | | 10,997 | | | | 497,064 | |
| Total Biotechnology | | | | | | | 2,459,653 | |
Commercial Services & Supplies — 2.3%
| | | | |
| Pointer Telocation Ltd. (Israel)* | | | 44,717 | | | | 516,481 | |
Communications Equipment — 17.8%
| |
| AudioCodes Ltd. (Israel)* | | | 67,240 | | | | 656,262 | |
| Ceragon Networks Ltd. (Israel)* | | | 139,810 | | | | 560,638 | |
| Gilat Satellite Networks Ltd. (Israel)* | | | 59,798 | | | | 506,594 | |
| Ituran Location and Control Ltd. (Israel) | | | 17,707 | | | | 602,923 | |
| RADCOM Ltd. (Israel)* | | | 24,903 | | | | 511,757 | |
| Radware Ltd. (Israel)* | | | 19,275 | | | | 509,246 | |
| Silicom Ltd. (Israel)* | | | 13,970 | | | | 551,815 | |
| Total Communications Equipment | | | | | | | 3,899,235 | |
Diversified Telecommunication — 4.8%
| |
| Bezeq The Israeli Telecommunication Corp. Ltd. (Israel) | | | 491,764 | | | | 520,797 | |
| magicJack VocalTec Ltd. (Israel)* | | | 62,865 | | | | 535,924 | |
| Total Diversified Telecommunication | | | | | | | 1,056,721 | |
Electronic Equipment, Instruments & Components — 4.8%
| |
| Orbotech Ltd. (Israel)* | | | 8,420 | | | | 540,901 | |
| Suny Cellular Communication Ltd. (Israel)* | | | 1,037,399 | | | | 502,004 | |
| Total Electronic Equipment, Instruments & Components | | | | | | | 1,042,905 | |
Health Care Equipment & Supplies — 2.5%
| |
| Mazor Robotics Ltd. (Israel)*(a) | | | 8,665 | | | | 542,602 | |
Internet Software & Services — 4.2%
| |
| Together Startup Network Ltd. (Israel)* | | | 278,295 | | | | 460,389 | |
| Wix.com Ltd. (Israel)* | | | 4,872 | | | | 462,840 | |
| Total Internet Software & Services | | | | | | | 923,229 | |
IT Services — 2.3%
| |
| Matrix IT Ltd. (Israel) | | | 47,848 | | | | 502,820 | |
Life Sciences Tools & Services — 2.2%
| |
| Compugen Ltd. (Israel)* | | | 150,926 | | | | 475,417 | |
Pharmaceuticals — 9.1%
| | | | | | | | |
Foamix Pharmaceuticals Ltd.
(Israel)* | | | 97,584 | | | | 561,108 | |
| Redhill Biopharma Ltd. (Israel)*(a) | | | 47,910 | | | | 372,261 | |
| Taro Pharmaceutical Industries Ltd.* | | | 4,633 | | | | 520,100 | |
| Teva Pharmaceutical Industries Ltd. (Israel)(a) | | | 22,519 | | | | 539,105 | |
| Total Pharmaceuticals | | | | | | | 1,992,574 | |
| | | | |
| Investments | | Shares | | Value |
Professional Services — 2.3%
| | | | | | | | |
| Danel Adir Yeoshua Ltd. (Israel) | | | 11,884 | | | $ | 515,204 | |
Semiconductors & Semiconductor Equipment — 11.7%
| |
| Camtek Ltd. (Israel) | | | 66,487 | | | | 547,188 | |
| Mellanox Technologies Ltd. (Israel)* | | | 6,338 | | | | 497,533 | |
| Nova Measuring Instruments Ltd. (Israel)* | | | 18,437 | | | | 516,052 | |
| SolarEdge Technologies, Inc.* | | | 9,754 | | | | 519,400 | |
| Tower Semiconductor Ltd. (Israel)* | | | 23,535 | | | | 485,998 | |
| Total Semiconductors & Semiconductor Equipment | | | | | | | 2,566,171 | |
Software — 15.2%
| | | | | | | | |
| Attunity Ltd. (Israel)* | | | 43,580 | | | | 735,630 | |
| Check Point Software Technologies Ltd. (Israel)* | | | 4,788 | | | | 539,464 | |
| CyberArk Software Ltd. (Israel)* | | | 7,617 | | | | 462,428 | |
| Hilan Ltd. (Israel) | | | 23,469 | | | | 525,723 | |
| Nice Ltd. (Israel)*(a) | | | 4,819 | | | | 527,199 | |
| Sapiens International Corp. NV (Israel) | | | 51,949 | | | | 536,114 | |
| Total Software | | | | | | | 3,326,558 | |
Technology Hardware, Storage & Peripherals — 2.3%
| |
| Stratasys Ltd.* | | | 25,614 | | | | 497,424 | |
Wireless Telecommunication Services — 4.8%
| |
| Cellcom Israel Ltd. (Israel)* | | | 92,491 | | | | 527,412 | |
| Partner Communications Co. Ltd. (Israel)* | | | 134,397 | | | | 515,673 | |
| Total Wireless Telecommunication Services | | | | | | | 1,043,085 | |
Total Common Stocks
(Cost $21,623,620) | | | | | | | 21,888,362 | |
MONEY MARKET FUND — 0.1%
| |
Morgan Stanley Institutional Liquidity Fund — Government
Portfolio, 1.81%(b) (Cost $16,885) | | | 16,885 | | | | 16,885 | |
Total Investments — 100.0%
(Cost $21,640,505) | | | | | | | 21,905,247 | |
| Liabilities in Excess of Other Assets — (0.0)%† | | | (9,047 | ) |
| Net Assets — 100.0% | | | | | | | $21,896,200 | |
| | |
| * | | Non-income producing security |
| † | | Less than 0.05% |
| (a) | | American Depositary Receipt |
| (b) | | Rate shown represents annualized 7-day yield as of July 31, 2018. |
| | | | |
| Country | | Value | | % of Net Assets |
| Israel | | $ | 19,837,329 | | | | 90.5 | % |
| United States | | | 2,067,918 | | | | 9.5 | |
| Total Investments | | | 21,905,247 | | | | 100.0 | |
| Liabilities in Excess of Other Assets | | | (9,047 | ) | | | 0.0 | ‡ |
| Net Assets | | | $21,896,200 | | | | 100.0% | |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments (continued)
ARK Israel Innovative Technology ETF
July 31, 2018
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
| • | Level 1 — Quoted prices in active markets for identical assets. |
| • | Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| • | Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of July 31, 2018, based upon the three levels defined above:
| | | | | | | | |
| ARK Israel Innovative Technology ETF | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets
| | | | | | | | | | | | | | | | |
| Common Stocks* | | $ | 21,888,362 | | | $ | — | | | $ | — | | | $ | 21,888,362 | |
| Money Market Fund | | | 16,885 | | | | — | | | | — | | | | 16,885 | |
| Total | | $ | 21,905,247 | | | $ | — | | | $ | — | | | $ | 21,905,247 | |
| * | Please refer to the Schedule of Investments to view securities segregated by industry type. |
There were no Level 2 or 3 investments held in the Fund as of July 31, 2018.
The Fund’s policy is to recognize transfers between levels at the beginning of the period. There were no transfers between levels for the year ended July 31, 2018, based on levels assigned to securities as of December 5, 2017.
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments
ARK Web x.0 ETF
July 31, 2018
| | | | |
| Investments | | Shares | | Value |
COMMON STOCKS — 99.4%
| | | | | | | | |
Automobiles — 6.1%
| | | | | | | | |
| Tesla, Inc.* | | | 136,655 | | | $ | 40,742,322 | |
Biotechnology — 2.1%
| | | | | | | | |
| Veracyte, Inc.* | | | 1,308,758 | | | | 14,173,849 | |
Consumer Finance — 3.1%
| | | | | | | | |
| LendingClub Corp.* | | | 5,005,717 | | | | 20,623,554 | |
Health Care Technology — 5.9%
| | | | | | | | |
| athenahealth, Inc.* | | | 109,023 | | | | 16,430,856 | |
| Medidata Solutions, Inc.* | | | 202,682 | | | | 15,061,300 | |
| Teladoc, Inc.* | | | 139,174 | | | | 8,329,564 | |
| Total Health Care Technology | | | | | | | 39,821,720 | |
Internet & Direct Marketing Retail — 11.2%
| |
| Amazon.com, Inc.* | | | 17,897 | | | | 31,810,844 | |
| JD.com, Inc. (China)*(a) | | | 607,292 | | | | 21,777,491 | |
| Netflix, Inc.* | | | 64,183 | | | | 21,658,553 | |
Total Internet & Direct Marketing Retail
| | | 75,246,888 | |
Internet Software & Services — 30.0%
| |
| 2U, Inc.* | | | 124,398 | | | | 9,411,953 | |
Alibaba Group Holding Ltd.
(China)*(a) | | | 82,827 | | | | 15,507,699 | |
| Alphabet, Inc., Class C* | | | 6,199 | | | | 7,545,795 | |
| Baidu, Inc. (China)*(a) | | | 100,203 | | | | 24,768,177 | |
| Facebook, Inc., Class A* | | | 84,645 | | | | 14,608,034 | |
| GrubHub, Inc.* | | | 27,897 | | | | 3,400,365 | |
| Hortonworks, Inc.* | | | 769,267 | | | | 13,400,631 | |
| MercadoLibre, Inc. (Argentina) | | | 62,582 | | | | 21,459,994 | |
| Shopify, Inc., Class A (Canada)* | | | 100,991 | | | | 13,957,966 | |
| Spotify Technology SA* | | | 108,435 | | | | 19,825,171 | |
| Tencent Holdings Ltd. (China)(a) | | | 497,911 | | | | 22,754,533 | |
| Twitter, Inc.* | | | 853,657 | | | | 27,206,049 | |
| Zillow Group, Inc., Class C* | | | 144,525 | | | | 8,050,042 | |
| Total Internet Software & Services | | | | | | | 201,896,409 | |
IT Services — 6.3%
| | | | | | | | |
| PayPal Holdings, Inc.* | | | 161,759 | | | | 13,286,884 | |
| Square, Inc., Class A* | | | 445,649 | | | | 28,811,208 | |
| Total IT Services | | | | | | | 42,098,092 | |
Real Estate Management & Development — 1.2%
| |
| Redfin Corp.* | | | 332,541 | | | | 8,147,255 | |
Semiconductors & Semiconductor Equipment — 11.8%
| |
| Advanced Micro Devices, Inc.* | | | 657,941 | | | | 12,060,058 | |
| NVIDIA Corp. | | | 118,711 | | | | 29,067,575 | |
| Taiwan Semiconductor Manufacturing Co. Ltd. (Taiwan)(a) | | | 550,417 | | | | 22,682,685 | |
| Xilinx, Inc. | | | 220,199 | | | | 15,869,742 | |
| Total Semiconductors & Semiconductor Equipment | | | | | | | 79,680,060 | |
| | | | |
| Investments | | Shares | | Value |
Software — 15.4%
| | | | | | | | |
| Adobe Systems, Inc.* | | | 46,639 | | | $ | 11,411,631 | |
| HubSpot, Inc.* | | | 102,423 | | | | 12,710,694 | |
| MGT Capital Investments, Inc.* | | | 1,168,499 | | | | 923,114 | |
| Microsoft Corp. | | | 128,300 | | | | 13,610,064 | |
| Red Hat, Inc.* | | | 134,720 | | | | 19,026,506 | |
| salesforce.com, Inc.* | | | 109,714 | | | | 15,047,275 | |
| ServiceNow, Inc.* | | | 39,181 | | | | 6,894,289 | |
| Snap, Inc., Class A* | | | 273,564 | | | | 3,419,550 | |
| Splunk, Inc.* | | | 141,714 | | | | 13,618,715 | |
| Zuora, Inc., Class A* | | | 268,604 | | | | 6,588,856 | |
| Total Software | | | | | | | 103,250,694 | |
Technology Hardware, Storage & Peripherals — 2.5%
| |
| Apple, Inc. | | | 88,354 | | | | 16,812,883 | |
Thrifts & Mortgage Finance — 2.1%
| |
| LendingTree, Inc.* | | | 57,948 | | | | 13,837,982 | |
Wireless Telecommunication Services — 1.7%
| |
| SoftBank Group Corp. (Japan)(a) | | | 282,203 | | | | 11,800,318 | |
Total Common Stocks
(Cost $654,443,398) | | | | | | | 668,132,026 | |
UNIT TRUST — 0.4%
| | | | | | | | |
Financials — 0.4%
| | | | | | | | |
Bitcoin Investment Trust
(Cost $833,713) | | | 225,786 | | | | 2,352,690 | |
MONEY MARKET FUND — 0.3%
| |
Morgan Stanley Institutional
Liquidity Fund — Government
Portfolio, 1.81%(b) (Cost $2,302,140) | | | 2,302,140 | | | | 2,302,140 | |
Total Investments — 100.1%
(Cost $657,579,251) | | | | | | | 672,786,856 | |
| Liabilities in Excess of Other Assets — (0.1)% | | | (510,783 | ) |
| Net Assets — 100.0% | | | | | | | $672,276,073 | |
| | |
| * | | Non-income producing security |
| (a) | | American Depositary Receipt |
| (b) | | Rate shown represents annualized 7-day yield as of July 31, 2018. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments (continued)
ARK Web x.0 ETF
July 31, 2018
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
| • | Level 1 — Quoted prices in active markets for identical assets. |
| • | Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| • | Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of July 31, 2018, based upon the three levels defined above:
| | | | | | | | |
| ARK Web x.0 ETF | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets
| | | | | | | | | | | | | | | | |
| Common Stocks* | | $ | 668,132,026 | | | $ | — | | | $ | — | | | $ | 668,132,026 | |
| Unit Trust* | | | 2,352,690 | | | | — | | | | — | | | | 2,352,690 | |
| Money Market Fund | | | 2,302,140 | | | | — | | | | — | | | | 2,302,140 | |
| Total | | $ | 672,786,856 | | | $ | — | | | $ | — | | | $ | 672,786,856 | |
| * | Please refer to the Schedule of Investments to view securities segregated by industry type. |
There were no Level 2 or 3 investments held in the Fund as of July 31, 2018.
The Fund’s policy is to recognize transfers between levels at the beginning of the period. There were no transfers between levels for the year ended July 31, 2018, based on levels assigned to securities as of July 31, 2017.
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments
The 3D Printing ETF
July 31, 2018
| | | | |
| Investments | | Shares | | Value |
COMMON STOCKS — 99.2%
| | | | | | | | |
Aerospace & Defense — 2.7%
| | | | | | | | |
| Arconic, Inc. | | | 30,341 | | | $ | 658,097 | |
| Hexcel Corp. | | | 926 | | | | 63,903 | |
| Moog, Inc., Class A | | | 7,298 | | | | 547,423 | |
| Total Aerospace & Defense | | | | | | | 1,269,423 | |
Air Freight & Logistics — 1.3%
| | | | | | | | |
| United Parcel Service, Inc., Class B | | | 5,164 | | | | 619,112 | |
Biotechnology — 4.9%
| | | | | | | | |
| Organovo Holdings, Inc.* | | | 1,954,779 | | | | 2,326,187 | |
Chemicals — 1.1%
| | | | | | | | |
| Arkema SA (France) | | | 525 | | | | 65,842 | |
| DowDuPont, Inc. | | | 968 | | | | 66,569 | |
| Eastman Chemical Co. | | | 636 | | | | 65,902 | |
| Evonik Industries AG (Germany) | | | 1,642 | | | | 60,770 | |
| Koninklijke DSM N.V. (Netherlands) | | | 606 | | | | 64,584 | |
| PolyOne Corp. | | | 1,362 | | | | 61,086 | |
| Praxair, Inc. | | | 388 | | | | 64,990 | |
| Toray Industries, Inc. (Japan) | | | 8,236 | | | | 63,780 | |
| Total Chemicals | | | | | | | 513,523 | |
Electrical Equipment — 1.4%
| | | | | | | | |
| AMETEK, Inc. | | | 8,369 | | | | 651,108 | |
Electronic Equipment, Instruments & Components — 12.6%
| |
| FARO Technologies, Inc.* | | | 10,659 | | | | 693,901 | |
| Hexagon AB, Class B (Sweden) | | | 10,824 | | | | 660,055 | |
| Renishaw PLC (United Kingdom) | | | 37,465 | | | | 2,689,840 | |
| Trimble, Inc.* | | | 53,168 | | | | 1,876,830 | |
| Total Electronic Equipment, Instruments & Components | | | | | | | 5,920,626 | |
Health Care Equipment & Supplies — 5.1%
| | | | |
| Align Technology, Inc.* | | | 1,664 | | | | 593,466 | |
| Conformis, Inc.* | | | 140,205 | | | | 134,597 | |
| K2M Group Holdings, Inc.* | | | 26,470 | | | | 539,194 | |
| Medtronic PLC | | | 6,588 | | | | 594,435 | |
| Stryker Corp. | | | 3,370 | | | | 550,152 | |
| Total Health Care Equipment & Supplies | | | | | | | 2,411,844 | |
Industrial Conglomerates — 2.6%
| | | | | | | | |
| 3M Co. | | | 319 | | | | 67,730 | |
| General Electric Co. | | | 42,376 | | | | 577,585 | |
| Siemens AG (Germany) | | | 4,239 | | | | 598,589 | |
| Total Industrial Conglomerates | | | | | | | 1,243,904 | |
Machinery — 19.7%
| | | | | | | | |
| ExOne Co. (The)* | | | 356,948 | | | | 2,470,080 | |
| Prodways Group SA (France)* | | | 549,751 | | | | 2,799,604 | |
| Proto Labs, Inc.* | | | 13,781 | | | | 1,717,802 | |
| Sandvik AB (Sweden) | | | 3,672 | | | | 67,172 | |
SLM Solutions Group AG
(Germany)* | | | 78,120 | | | | 2,256,325 | |
| Total Machinery | | | | | | | 9,310,983 | |
| | | | |
| Investments | | Shares | | Value |
Metals & Mining — 0.3%
| | | | | | | | |
| Allegheny Technologies, Inc.* | | | 2,412 | | | $ | 67,054 | |
| Carpenter Technology Corp. | | | 1,139 | | | | 62,383 | |
| Total Metals & Mining | | | | | | | 129,437 | |
Professional Services — 2.5%
| | | | | | | | |
| Arrk Corp. (Japan)* | | | 595,101 | | | | 596,086 | |
| Bertrandt AG (Germany) | | | 5,947 | | | | 601,529 | |
| Total Professional Services | | | | | | | 1,197,615 | |
Semiconductors & Semiconductor Equipment — 1.0%
| |
| Ultra Clean Holdings, Inc.* | | | 36,310 | | | | 487,280 | |
Software — 22.7%
| | | | | | | | |
| ANSYS, Inc.* | | | 10,249 | | | | 1,730,851 | |
| Autodesk, Inc.* | | | 13,748 | | | | 1,765,793 | |
| Dassault Systemes (France) | | | 12,165 | | | | 1,817,965 | |
| Materialise NV (Belgium)*(a) | | | 140,093 | | | | 1,763,771 | |
| Microsoft Corp. | | | 17,740 | | | | 1,881,859 | |
| PTC, Inc.* | | | 19,077 | | | | 1,753,367 | |
| Total Software | | | | | | | 10,713,606 | |
Technology Hardware, Storage & Peripherals — 21.3%
| |
| 3D Systems Corp.* | | | 182,377 | | | | 2,219,528 | |
| Eastman Kodak Co.* | | | 16,866 | | | | 53,128 | |
| HP Inc. | | | 118,333 | | | | 2,731,126 | |
| MGI Digital Graphic Technology (France)* | | | 35,597 | | | | 2,505,834 | |
| Stratasys Ltd.* | | | 130,432 | | | | 2,532,989 | |
| Total Technology Hardware, Storage & Peripherals | | | | | | | 10,042,605 | |
Total Common Stocks
(Cost $45,866,617) | | | | | | | 46,837,253 | |
PREFERRED STOCK — 0.1%
| | | | | | | | |
Household Products — 0.1%
| | | | | | | | |
Henkel AG & Co. KGaA (Germany)
| | | | | | | | |
| (Cost $63,842) | | | 499 | | | | 62,581 | |
MONEY MARKET FUND — 0.4%
| |
Morgan Stanley Institutional
Liquidity Fund — Government
Portfolio, 1.81%(b) (Cost $193,565) | | | 193,565 | | | | 193,565 | |
Total Investments — 99.7%
(Cost $46,124,024) | | | | | | | 47,093,399 | |
| Other Assets in Excess of Liabilities – 0.3% | | | 126,368 | |
| Net Assets — 100.0% | | | | | | | $47,219,767 | |
| | |
| * | | Non-income producing security |
| (a) | | American Depositary Receipt |
| (b) | | Rate shown represents annualized 7-day yield as of July 31, 2018. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Schedule of Investments (continued)
The 3D Printing ETF
July 31, 2018
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
| • | Level 1 — Quoted prices in active markets for identical assets. |
| • | Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| • | Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments). |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of July 31, 2018, based upon the three levels defined above:
| | | | | | | | |
| The 3D Printing ETF | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets
| | | | | | | | | | | | | | | | |
| Common Stocks* | | $ | 46,837,253 | | | $ | — | | | $ | — | | | $ | 46,837,253 | |
| Preferred Stock* | | | 62,581 | | | | — | | | | — | | | | 62,581 | |
| Money Market Fund | | | 193,565 | | | | — | | | | — | | | | 193,565 | |
| Total | | $ | 47,093,399 | | | $ | — | | | $ | — | | | $ | 47,093,399 | |
| * | Please refer to the Schedule of Investments to view securities segregated by industry type. |
There were no Level 2 or 3 investments held in the Fund as of July 31, 2018.
The Fund’s policy is to recognize transfers between levels at the beginning of the period. There were no transfers between levels for the year ended July 31, 2018, based on levels assigned to securities as of July 31, 2017.
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Statements of Assets and Liabilities
July 31, 2018
| | | | | | | | | | | | |
| | | ARK
Genomic
Revolution
Multi-Sector
ETF | | ARK
Industrial
Innovation
ETF | | ARK
Innovation
ETF | | ARK
Israel
Innovative
Technology
ETF | | ARK
Web x.0
ETF | | The 3D
Printing
ETF |
ASSETS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Investments in non-affiliated securities at value (Note 2) | | $ | 227,373,158 | | | $ | 155,446,866 | | | $ | 907,434,063 | | | $ | 21,905,247 | | | $ | 672,786,856 | | | $ | 47,093,399 | |
| Investments in affiliated securities at value (Note 2) | | | 4,728,432 | | | | — | | | | 264,089,417 | | | | — | | | | — | | | | — | |
Receivables:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Dividends and Interest | | | 16,103 | | | | 10,076 | | | | 3,323 | | | | 110 | | | | 2,038 | | | | 333 | |
| Capital shares sold | | | — | | | | 3,493,202 | | | | — | | | | — | | | | — | | | | — | |
| Investment securities sold | | | 5,575,199 | | | | 237,610 | | | | 22,741,149 | | | | — | | | | 27,191,399 | | | | 350,282 | |
| Reclaims | | | 844 | | | | 11,078 | | | | — | | | | — | | | | 1,465 | | | | 6,805 | |
| Total Assets | | | 237,693,736 | | | | 159,198,832 | | | | 1,194,267,952 | | | | 21,905,357 | | | | 699,981,758 | | | | 47,450,819 | |
LIABILITIES:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Due to custodian | | | 6 | | | | — | | | | 8 | | | | — | | | | — | | | | 40 | |
| Due to custodian for foreign currency | | | — | | | | — | | | | — | | | | 9 | | | | — | | | | 202,548 | |
Payables:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Capital shares purchased | | | — | | | | — | | | | — | | | | — | | | | 13,776,149 | | | | — | |
| Investment securities purchased | | | 5,435,359 | | | | 3,656,027 | | | | 22,936,056 | | | | — | | | | 13,496,598 | | | | — | |
| Management fees (Note 3) | | | 143,393 | | | | 95,292 | | | | 743,703 | | | | 8,961 | | | | 432,938 | | | | 28,033 | |
| Other accrued expenses | | | — | | | | — | | | | — | | | | 187 | | | | — | | | | 431 | |
| Total Liabilities | | | 5,578,758 | | | | 3,751,319 | | | | 23,679,767 | | | | 9,157 | | | | 27,705,685 | | | | 231,052 | |
| NET ASSETS | | $ | 232,114,978 | | | $ | 155,447,513 | | | $ | 1,170,588,185 | | | $ | 21,896,200 | | | $ | 672,276,073 | | | $ | 47,219,767 | |
NET ASSETS CONSIST OF:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Paid-in capital | | $ | 212,952,622 | | | $ | 138,857,034 | | | $ | 1,074,128,600 | | | $ | 21,936,884 | | | $ | 610,060,569 | | | $ | 47,702,414 | |
| Accumulated net investment loss | | | (101,095 | ) | | | 130,568 | | | | 1,582,758 | | | | 343,718 | | | | 1,527,144 | | | | — | |
| Accumulated net realized gain (loss) on investments and on foreign currency transactions | | | (276,502 | ) | | | 536,875 | | | | 14,062,681 | | | | (649,144 | ) | | | 45,480,755 | | | | (1,451,286 | ) |
| Net unrealized appreciation on investments and on foreign currency translations | | | 19,539,953 | | | | 15,923,036 | | | | 80,814,146 | | | | 264,742 | | | | 15,207,605 | | | | 968,639 | |
| NET ASSETS | | $ | 232,114,978 | | | $ | 155,447,513 | | | $ | 1,170,588,185 | | | $ | 21,896,200 | | | $ | 672,276,073 | | | $ | 47,219,767 | |
| Shares outstanding | | | 7,905,000 | | | | 4,450,000 | | | | 26,300,000 | | | | 1,050,001 | | | | 12,200,000 | | | | 1,950,001 | |
| Net asset value, per share | | $ | 29.36 | | | $ | 34.93 | | | $ | 44.51 | | | $ | 20.85 | | | $ | 55.10 | | | $ | 24.22 | |
| Investments in non-affiliated securities at cost | | $ | 208,265,109 | | | $ | 139,523,830 | | | $ | 838,156,926 | | | $ | 21,640,505 | | | $ | 657,579,251 | | | $ | 46,124,024 | |
| Investments in affiliated securities at cost | | $ | 4,296,528 | | | $ | — | | | $ | 252,552,408 | | | $ | — | | | $ | — | | | $ | — | |
| Foreign currency at cost | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
For the Year Ended July 31, 2018
| | | | | | | | | | | | |
| | | ARK
Genomic
Revolution
Multi-Sector ETF | | ARK
Industrial
Innovation
ETF | | ARK
Innovation
ETF | | ARK
Israel
Innovative
Technology ETF(1) | | ARK
Web x.0
ETF | | The 3D
Printing
ETF |
INVESTMENT INCOME:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Unaffiliated dividend income | | $ | 103,863 | | | $ | 770,034 | | | $ | 2,334,010 | | | $ | 81,282 | | | $ | 2,050,938 | | | $ | 231,864 | |
| Foreign withholding tax | | | — | | | | (37,601 | ) | | | (86,910 | ) | | | (19,773 | ) | | | (135,384 | ) | | | (8,011 | ) |
| Total Income | | | 103,863 | | | | 732,433 | | | | 2,247,100 | | | | 61,509 | | | | 1,915,554 | | | | 223,853 | |
EXPENSES:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Management fees (Note 3) | | | 721,664 | | | | 923,114 | | | | 3,982,025 | | | | 63,658 | | | | 2,499,923 | | | | 297,199 | |
| Other expenses | | | — | | | | — | | | | — | | | | 1,326 | | | | — | | | | 4,572 | |
| Total Expenses | | | 721,664 | | | | 923,114 | | | | 3,982,025 | | | | 64,984 | | | | 2,499,923 | | | | 301,771 | |
| Net Investment Loss(2) | | | (617,801 | ) | | | (190,681 | ) | | | (1,734,925 | ) | | | (3,475 | ) | | | (584,369 | ) | | | (77,918 | ) |
NET REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS AND FOREIGN CURRENCY TRANSLATION:
| | | | | | | | | | | | | | | | | | | | | | | | |
Net realized gain (loss) on:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Investments in non-affiliated securities | | | 2,160,825 | | | | 2,970,038 | | | | 26,550,226 | | | | (310,079 | ) | | | 52,337,328 | | | | (602,365 | ) |
| Investments in affiliated securities | | | — | | | | — | | | | (3,808,710 | ) | | | — | | | | — | | | | — | |
| Foreign currency transactions | | | — | | | | — | | | | — | | | | 7,938 | | | | — | | | | (1,481 | ) |
| In-kind redemptions-Non-affiliated securities | | | — | | | | 7,521,145 | | | | 30,452,514 | | | | 229,143 | | | | 28,597,770 | | | | 655,720 | |
| In-kind redemptions-Affiliated securities | | | — | | | | — | | | | 1,786,939 | | | | — | | | | — | | | | — | |
| Net realized gain (loss) | | | 2,160,825 | | | | 10,491,183 | | | | 54,980,969 | | | | (72,998 | ) | | | 80,935,098 | | | | 51,874 | |
Change in unrealized appreciation (depreciation) on:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Investments in non-affiliated securities | | | 16,910,933 | | | | 4,650,537 | | | | 60,102,394 | | | | 264,742 | | | | 2,212,690 | | | | (1,372,466 | ) |
| Investments in affiliated securities | | | 431,904 | | | | — | | | | 11,506,361 | | | | — | | | | — | | | | — | |
| Foreign currency translation | | | — | | | | — | | | | — | | | | — | | | | — | | | | (887 | ) |
| Change in unrealized appreciation (depreciation) | | | 17,342,837 | | | | 4,650,537 | | | | 71,608,755 | | | | 264,742 | | | | 2,212,690 | | | | (1,373,353 | ) |
| Net realized and unrealized gain (loss) on investments and foreign currency translation | | | 19,503,662 | | | | 15,141,720 | | | | 126,589,724 | | | | 191,744 | | | | 83,147,788 | | | | (1,321,479 | ) |
| Net Increase (Decrease) in Net Assets Resulting From Operations | | $ | 18,885,861 | | | $ | 14,951,039 | | | $ | 124,854,799 | | | $ | 188,269 | | | $ | 82,563,419 | | | $ | (1,399,397 | ) |
| (1) | Represents the period December 5, 2017 (commencement of operations) to July 31, 2018. |
| (2) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Statements of Changes in Net Assets
| | | | | | | | | | | | |
| | | ARK
Genomic Revolution Multi-Sector ETF | | ARK
Industrial Innovation ETF |
| | | Year Ended
July 31, 2018 | | Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | Year Ended
July 31, 2018 | | Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 |
OPERATIONS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Net investment loss(1) | | $ | (617,801 | ) | | $ | (68,841 | ) | | $ | (50,465 | ) | | $ | (190,681 | ) | | $ | (80,830 | ) | | $ | (51,535 | ) |
| Net realized gain (loss) on investments and foreign currency transactions | | | 2,160,825 | | | | 80,086 | | | | (957,587 | ) | | | 10,491,183 | | | | 251,068 | | | | (353,436 | ) |
| Net change in unrealized appreciation (depreciation) on investments and foreign currency translations | | | 17,342,837 | | | | 2,381,175 | | | | (133,962 | ) | | | 4,650,537 | | | | 9,683,713 | | | | 2,582,436 | |
| Net increase (decrease) in net assets resulting from operations | | | 18,885,861 | | | | 2,392,420 | | | | (1,142,014 | ) | | | 14,951,039 | | | | 9,853,951 | | | | 2,177,465 | |
| DISTRIBUTIONS TO SHAREHOLDERS FROM: | | | | | | | | | | | | | | | | | | | | | | | | |
| Net investment income | | | — | | | | — | | | | — | | | | (81,970 | ) | | | — | | | | — | |
| Net realized gains | | | (706,172 | ) | | | — | | | | — | | | | (1,694,245 | ) | | | — | | | | (131,180 | ) |
| Total distributions to shareholders | | | (706,172 | ) | | | — | | | | — | | | | (1,776,215 | ) | | | — | | | | (131,180 | ) |
SHAREHOLDER TRANSACTIONS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Proceeds from shares sold | | | 190,475,551 | | | | 14,574,633 | | | | — | | | | 92,615,079 | | | | 40,870,717 | | | | 977,801 | |
| Cost of shares redeemed | | | — | | | | (809,562 | ) | | | — | | | | (16,919,964 | ) | | | — | | | | — | |
| Net increase in net assets resulting from shareholder transactions | | | 190,475,551 | | | | 13,765,071 | | | | — | | | | 75,695,115 | | | | 40,870,717 | | | | 977,801 | |
| Increase (Decrease) in net assets | | | 208,655,240 | | | | 16,157,491 | | | | (1,142,014 | ) | | | 88,869,939 | | | | 50,724,668 | | | | 3,024,086 | |
NET ASSETS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Beginning of period | | | 23,459,738 | | | | 7,302,247 | | | | 8,444,261 | | | | 66,577,574 | | | | 15,852,906 | | | | 12,828,820 | |
| End of period | | $ | 232,114,978 | | | $ | 23,459,738 | | | $ | 7,302,247 | | | $ | 155,447,513 | | | $ | 66,577,574 | | | $ | 15,852,906 | |
| Accumulated net investment income (loss) included in net assets at end of period | | $ | (101,095 | ) | | $ | (52,210 | ) | | $ | (30,201 | ) | | $ | 130,568 | | | $ | 3,602 | | | $ | (35,661 | ) |
CHANGES IN SHARES OUTSTANDING:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Shares outstanding, beginning of period | | | 1,055,000 | | | | 405,000 | | | | 405,000 | | | | 2,250,000 | | | | 750,000 | | | | 700,000 | |
| Shares sold | | | 6,850,000 | | | | 700,000 | | | | — | | | | 2,700,000 | | | | 1,500,000 | | | | 50,000 | |
| Shares redeemed | | | — | | | | (50,000 | ) | | | — | | | | (500,000 | ) | | | — | | | | — | |
| Shares outstanding, end of period | | | 7,905,000 | | | | 1,055,000 | | | | 405,000 | | | | 4,450,000 | | | | 2,250,000 | | | | 750,000 | |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| (1) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Statements of Changes in Net Assets (continued)
| | | | | | | | |
| | | ARK
Innovation ETF | | ARK Israel Innovative
Technology ETF |
| | | Year Ended
July 31, 2018 | | Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | December 5, 2017* to
July 31, 2018 |
OPERATIONS:
| | | | | | | | | | | | | | | | |
| Net investment loss(1) | | $ | (1,734,925 | ) | | $ | (144,804 | ) | | $ | (59,532 | ) | | $ | (3,475 | ) |
Net realized gain (loss) on investments and foreign
currency transactions | | | 54,980,969 | | | | 423,491 | | | | (632,717 | ) | | | (72,998 | ) |
Net change in unrealized appreciation (depreciation) on
investments and foreign currency translations | | | 71,608,755 | | | | 8,242,548 | | | | 1,172,869 | | | | 264,742 | |
| Net increase in net assets resulting from operations | | | 124,854,799 | | | | 8,521,235 | | | | 480,620 | | | | 188,269 | |
| DISTRIBUTIONS TO SHAREHOLDERS FROM: | | | | | | | | | | | | | | | | |
| Net investment income | | | (916,951 | ) | | | — | | | | — | | | | — | |
| Net realized gains | | | (4,032,291 | ) | | | — | | | | (186,040 | ) | | | — | |
| Total distributions to shareholders | | | (4,949,242 | ) | | | — | | | | (186,040 | ) | | | — | |
SHAREHOLDER TRANSACTIONS:
| | | | | | | | | | | | | | | | |
| Proceeds from shares sold | | | 1,044,758,824 | | | | 68,021,355 | | | | 1,955,672 | | | | 23,747,738 | |
| Cost of shares redeemed | | | (79,889,522 | ) | | | — | | | | — | | | | (2,039,807 | ) |
| Net increase in net assets resulting from shareholder transactions | | | 964,869,302 | | | | 68,021,355 | | | | 1,955,672 | | | | 21,707,931 | |
| Increase in net assets | | | 1,084,774,859 | | | | 76,542,590 | | | | 2,250,252 | | | | 21,896,200 | |
NET ASSETS:
| | | | | | | | | | | | | | | | |
| Beginning of period | | | 85,813,326 | | | | 9,270,736 | | | | 7,020,484 | | | | — | |
| End of period | | $ | 1,170,588,185 | | | $ | 85,813,326 | | | $ | 9,270,736 | | | $ | 21,896,200 | |
Accumulated net investment income (loss) included in
net assets at end of period | | $ | 1,582,758 | | | $ | 1,783 | | | $ | (41,508 | ) | | $ | 343,718 | |
CHANGES IN SHARES OUTSTANDING:
| | | | | | | | | | | | | | | | |
| Shares outstanding, beginning of period | | | 2,900,000 | | | | 450,000 | | | | 350,000 | | | | — | |
| Shares sold | | | 25,450,000 | | | | 2,450,000 | | | | 100,000 | | | | 1,150,001 | |
| Shares redeemed | | | (2,050,000 | ) | | | — | | | | — | | | | (100,000 | ) |
| Shares outstanding, end of period | | | 26,300,000 | | | | 2,900,000 | | | | 450,000 | | | | 1,050,001 | |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| * | Commencement of operations. |
| (1) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Statements of Changes in Net Assets (concluded)
| | | | | | | | | | | | |
| | | ARK Web x.0 ETF | | The 3D Printing ETF |
| | | Year Ended
July 31, 2018 | | Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | Year Ended
July 31, 2018 | | Period Ended
July 31, 2017† | | July 19, 2016* to
August 31, 2016 |
OPERATIONS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Net investment income (loss)(1) | | $ | (584,369 | ) | | $ | (147,756 | ) | | $ | (98,894 | ) | | $ | (77,918 | ) | | $ | (22,287 | ) | | $ | 868 | |
| Net realized gain (loss) on investments and foreign currency transactions | | | 80,935,098 | | | | 983,763 | | | | (291,724 | ) | | | 51,874 | | | | 546,453 | | | | (110 | ) |
| Net change in unrealized appreciation (depreciation) on investments and foreign currency translations | | | 2,212,690 | | | | 10,117,020 | | | | 2,093,005 | | | | (1,373,353 | ) | | | 2,211,249 | | | | 130,743 | |
| Net increase (decrease) in net assets resulting from operations | | | 82,563,419 | | | | 10,953,027 | | | | 1,702,387 | | | | (1,399,397 | ) | | | 2,735,415 | | | | 131,501 | |
| DISTRIBUTIONS TO SHAREHOLDERS FROM: | | | | | | | | | | | | | | | | | | | | | | | | |
| Net investment income | | | (656,264 | ) | | | — | | | | — | | | | — | | | | (759 | ) | | | — | |
| Net realized gains | | | (4,205,645 | ) | | | — | | | | (318,120 | ) | | | (1,001,091 | ) | | | — | | | | — | |
| Total distributions to shareholders | | | (4,861,909 | ) | | | — | | | | (318,120 | ) | | | (1,001,091 | ) | | | (759 | ) | | | — | |
SHAREHOLDER TRANSACTIONS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Proceeds from shares sold | | | 605,904,119 | | | | 42,502,347 | | | | 1,159,138 | | | | 16,416,211 | | | | 30,201,634 | | | | 6,111,000 | |
| Cost of shares redeemed | | | (79,438,968 | ) | | | — | | | | — | | | | (2,522,373 | ) | | | (3,452,374 | ) | | | — | |
| Net increase in net assets resulting from shareholder transactions | | | 526,465,151 | | | | 42,502,347 | | | | 1,159,138 | | | | 13,893,838 | | | | 26,749,260 | | | | 6,111,000 | |
| Increase in net assets | | | 604,166,661 | | | | 53,455,374 | | | | 2,543,405 | | | | 11,493,350 | | | | 29,483,916 | | | | 6,242,501 | |
NET ASSETS:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Beginning of period | | | 68,109,412 | | | | 14,654,038 | | | | 12,110,633 | | | | 35,726,417 | | | | 6,242,501 | | | | — | |
| End of period | | $ | 672,276,073 | | | $ | 68,109,412 | | | $ | 14,654,038 | | | $ | 47,219,767 | | | $ | 35,726,417 | | | $ | 6,242,501 | |
| Accumulated net investment income (loss) included in net assets at end of period | | $ | 1,527,144 | | | $ | 4,091 | | | $ | (65,914 | ) | | $ | — | | | $ | — | | | $ | 758 | |
CHANGES IN SHARES OUTSTANDING:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Shares outstanding, beginning of period | | | 1,850,000 | | | | 600,000 | | | | 550,000 | | | | 1,400,001 | | | | 300,001 | | | | — | |
| Shares sold | | | 11,950,000 | | | | 1,250,000 | | | | 50,000 | | | | 650,000 | | | | 1,250,000 | | | | 300,001 | |
| Shares redeemed | | | (1,600,000 | ) | | | — | | | | — | | | | (100,000 | ) | | | (150,000 | ) | | | — | |
| Shares outstanding, end of period | | | 12,200,000 | | | | 1,850,000 | | | | 600,000 | | | | 1,950,001 | | | | 1,400,001 | | | | 300,001 | |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| * | Commencement of operations. |
| (1) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Financial Highlights
ARK Genomic Revolution Multi-Sector ETF
For a share outstanding throughout each period presented.
| | | | | | | | |
| | | Year Ended
July 31, 2018 | | For the
Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | For the Period
October 31, 2014(1) Through
August 31, 2015 |
Per Share Data:
| | | | | | | | | | | | | | | | |
| Net asset value, beginning of period | | $ | 22.24 | | | $ | 18.03 | | | $ | 20.85 | | | $ | 20.00 | |
| Net investment loss(2) | | | (0.18 | ) | | | (0.12 | ) | | | (0.12 | ) | | | (0.09 | ) |
| Net realized and unrealized gain (loss) on investments | | | 7.63 | | | | 4.33 | | | | (2.70 | ) | | | 0.94 | |
| Total gain (loss) from investment operations | | | 7.45 | | | | 4.21 | | | | (2.82 | ) | | | 0.85 | |
| Distributions to shareholders: | | | | | | | | | | | | | | | | |
| Realized gains | | | (0.33 | ) | | | — | | | | — | | | | — | |
| Total distributions | | | (0.33 | ) | | | — | | | | — | | | | — | |
| Net asset value, end of period | | $ | 29.36 | | | $ | 22.24 | | | $ | 18.03 | | | $ | 20.85 | |
| Market value, end of period | | $ | 29.40 | | | $ | 22.29 | | | $ | 18.01 | | | $ | 21.13 | |
| Total Return at Net Asset Value(3) | | | 33.80 | % | | | 23.34 | % | | | (13.52 | )% | | | 4.25 | % |
| Total Return at Market Value(3) | | | 33.66 | % | | | 23.77 | % | | | (14.77 | )% | | | 5.65 | % |
Ratios/Supplemental Data:
| | | | | | | | | | | | | | | | |
| Net assets, end of period (000’s omitted) | | $ | 232,115 | | | $ | 23,460 | | | $ | 7,302 | | | $ | 8,444 | |
Ratio to average net assets of:
| | | | | | | | | | | | | | | | |
| Expenses | | | 0.75 | % | | | 0.75 | %(4) | | | 0.90 | % | | | 0.95 | %(4) |
| Net investment loss(5) | | | (0.64 | )% | | | (0.67 | )%(4) | | | (0.67 | )% | | | (0.47 | )%(4) |
| Portfolio turnover rate(6) | | | 80 | % | | | 65 | % | | | 77 | % | | | 65 | % |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| (1) | Commencement of operations. |
| (2) | Based on average daily shares outstanding. |
| (3) | Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value. Market value total return is calculated assuming an initial investment made at the market value at the beginning of the period, reinvestment of all dividends, and distributions at market value during the period, and sale at the market value on the last day of the period. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Total return calculated for a period of less than one year is not annualized. |
| (5) | Net investment loss represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
| (6) | Portfolio turnover rate is not annualized and excludes the value of portfolio securities received or delivered as a result of in-kind creations or redemptions of the Fund’s capital shares. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Financial Highlights (continued)
ARK Industrial Innovation ETF
For a share outstanding throughout each period presented.
| | | | | | | | |
| | | Year Ended
July 31, 2018 | | For the
Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | For the Period
September 30, 2014(1) Through
August 31, 2015 |
Per Share Data:
| | | | | | | | | | | | | | | | |
| Net asset value, beginning of period | | $ | 29.59 | | | $ | 21.14 | | | $ | 18.33 | | | $ | 20.00 | |
| Net investment loss(2) | | | (0.05 | ) | | | (0.07 | ) | | | (0.07 | ) | | | (0.07 | ) |
| Net realized and unrealized gain (loss) on investments | | | 5.89 | | | | 8.52 | | | | 3.07 | | | | (1.60 | ) |
| Total gain (loss) from investment operations | | | 5.84 | | | | 8.45 | | | | 3.00 | | | | (1.67 | ) |
Distributions to shareholders:
| | | | | | | | | | | | | | | | |
| Net investment income | | | (0.02 | ) | | | — | | | | — | | | | — | |
| Realized gains | | | (0.48 | ) | | | — | | | | (0.19 | ) | | | — | |
| Total distributions | | | (0.50 | ) | | | — | | | | (0.19 | ) | | | — | |
| Net asset value, end of period | | $ | 34.93 | | | $ | 29.59 | | | $ | 21.14 | | | $ | 18.33 | |
| Market value, end of period | | $ | 35.01 | | | $ | 29.63 | | | $ | 21.14 | | | $ | 18.43 | |
| Total Return at Net Asset Value(3) | | | 19.86 | % | | | 39.97 | % | | | 16.43 | % | | | (8.35 | )% |
| Total Return at Market Value(3) | | | 19.98 | % | | | 40.16 | % | | | 15.84 | % | | | (7.85 | )% |
Ratios/Supplemental Data:
| | | | | | | | | | | | | | | | |
| Net assets, end of period (000’s omitted) | | $ | 155,448 | | | $ | 66,578 | | | $ | 15,853 | | | $ | 12,829 | |
Ratio to average net assets of:
| | | | | | | | | | | | | | | | |
| Expenses | | | 0.75 | % | | | 0.75 | %(4) | | | 0.89 | % | | | 0.95 | %(4) |
| Net investment loss(5) | | | (0.15 | )% | | | (0.31 | )%(4) | | | (0.38 | )% | | | (0.40 | )%(4) |
| Portfolio turnover rate(6) | | | 57 | % | | | 44 | % | | | 67 | % | | | 86 | % |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| (1) | Commencement of operations. |
| (2) | Based on average daily shares outstanding. |
| (3) | Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value. Market value total return is calculated assuming an initial investment made at the market value at the beginning of the period, reinvestment of all dividends, and distributions at market value during the period, and sale at the market value on the last day of the period. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Total return calculated for a period of less than one year is not annualized. |
| (5) | Net investment loss represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
| (6) | Portfolio turnover rate is not annualized and excludes the value of portfolio securities received or delivered as a result of in-kind creations or redemptions of the Fund’s capital shares. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Financial Highlights (continued)
ARK Innovation ETF
For a share outstanding throughout each period presented.
| | | | | | | | |
| | | Year Ended
July 31, 2018 | | For the
Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | For the Period
October 31, 2014(1) Through
August 31, 2015 |
Per Share Data:
| | | | | | | | | | | | | | | | |
| Net asset value, beginning of period | | $ | 29.59 | | | $ | 20.60 | | | $ | 20.06 | | | $ | 20.00 | |
| Net investment loss(2) | | | (0.13 | ) | | | (0.15 | ) | | | (0.15 | ) | | | (0.12 | ) |
| Net realized and unrealized gain on investments | | | 15.54 | (3) | | | 9.14 | | | | 1.16 | | | | 0.18 | |
| Total gain from investment operations | | | 15.41 | | | | 8.99 | | | | 1.01 | | | | 0.06 | |
| Distributions to shareholders: | | | | | | | | | | | | | | | | |
| Net investment income | | | (0.09 | ) | | | — | | | | — | | | | — | |
| Realized gains | | | (0.40 | ) | | | — | | | | (0.47 | ) | | | — | |
| Total distributions | | | (0.49 | ) | | | — | | | | (0.47 | ) | | | — | |
| Net asset value, end of period | | $ | 44.51 | | | $ | 29.59 | | | $ | 20.60 | | | $ | 20.06 | |
| Market value, end of period | | $ | 44.55 | | | $ | 29.62 | | | $ | 20.61 | | | $ | 20.10 | |
| Total Return at Net Asset Value(4) | | | 52.38 | %(3) | | | 43.64 | % | | | 4.98 | % | | | 0.30 | % |
| Total Return at Market Value(4) | | | 52.38 | %(3) | | | 43.72 | % | | | 4.90 | % | | | 0.50 | % |
Ratios/Supplemental Data:
| | | | | | | | | | | | | | | | |
| Net assets, end of period (000’s omitted) | | $ | 1,170,588 | | | $ | 85,813 | | | $ | 9,271 | | | $ | 7,020 | |
Ratio to average net assets of:
| | | | | | | | | | | | | | | | |
| Expenses | | | 0.75 | % | | | 0.75 | %(5) | | | 0.89 | % | | | 0.95 | %(5) |
| Net investment loss(6) | | | (0.33 | )% | | | (0.67 | )%(5) | | | (0.76 | )% | | | (0.69 | )%(5) |
| Portfolio turnover rate(7) | | | 89 | % | | | 70 | % | | | 110 | % | | | 108 | % |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| (1) | Commencement of operations. |
| (2) | Based on average daily shares outstanding. |
| (3) | The Adviser has reimbursed the Fund $15,998.59 for a procedural error. The impact was deemed immaterial to net realized and unrealized gain on investments and the Fund’s total return, representing less than $0.005 per share. |
| (4) | Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value. Market value total return is calculated assuming an initial investment made at the market value at the beginning of the period, reinvestment of all dividends, and distributions at market value during the period, and sale at the market value on the last day of the period. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Total return calculated for a period of less than one year is not annualized. |
| (6) | Net investment loss represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
| (7) | Portfolio turnover rate is not annualized and excludes the value of portfolio securities received or delivered as a result of in-kind creations or redemptions of the Fund’s capital shares. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Financial Highlights (continued)
ARK Israel Innovative Technology ETF
For a share outstanding throughout each period presented.
| | |
| | | For the Period
December 5, 2017(1) Through
July 31, 2018 |
Per Share Data:
| | | | |
| Net asset value, beginning of period | | $ | 20.00 | |
| Net investment income(2) | | | (0.00 | )(3) |
| Net realized and unrealized gain on investments | | | 0.85 | |
| Total gain from investment operations | | | 0.85 | |
| Net asset value, end of period | | $ | 20.85 | |
| Market value, end of period | | $ | 21.04 | |
| Total Return at Net Asset Value(4) | | | 4.27 | % |
| Total Return at Market Value(4) | | | 5.20 | % |
Ratios/Supplemental Data:
| | | | |
| Net assets, end of period (000’s omitted) | | $ | 21,896 | |
Ratio to average net assets of:
| | | | |
| Expenses | | | 0.49 | %(5) |
| Net investment loss(6) | | | (0.03 | )%(5) |
| Portfolio turnover rate(7) | | | 40 | % |
| (1) | Commencement of operations. |
| (2) | Based on average daily shares outstanding. |
| (3) | Amount represents less than $0.005. |
| (4) | Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value. Market value total return is calculated assuming an initial investment made at the market value at the beginning of the period, reinvestment of all dividends, and distributions at market value during the period, and sale at the market value on the last day of the period. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Total return calculated for a period of less than one year is not annualized. |
| (6) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
| (7) | Portfolio turnover rate is not annualized and excludes the value of portfolio securities received or delivered as a result of in-kind creations or redemptions of the Fund’s capital shares. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Financial Highlights (continued)
ARK Web x.0 ETF
For a share outstanding throughout each period presented.
| | | | | | | | |
| | | Year Ended
July 31, 2018 | | For the
Period Ended
July 31, 2017† | | Year Ended
August 31, 2016 | | For the Period
September 30, 2014(1) Through
August 31, 2015 |
Per Share Data:
| | | | | | | | | | | | | | | | |
| Net asset value, beginning of period | | $ | 36.82 | | | $ | 24.42 | | | $ | 22.02 | | | $ | 20.00 | |
| Net investment loss(2) | | | (0.09 | ) | | | (0.17 | ) | | | (0.17 | ) | | | (0.13 | ) |
| Net realized and unrealized gain on investments | | | 19.32 | (3) | | | 12.57 | | | | 3.10 | | | | 2.15 | |
| Total gain from investment operations | | | 19.23 | | | | 12.40 | | | | 2.93 | | | | 2.02 | |
| Distributions to shareholders: | | | | | | | | | | | | | | | | |
| Net investment income | | | (0.13 | ) | | | — | | | | — | | | | — | |
| Realized gains | | | (0.82 | ) | | | — | | | | (0.53 | ) | | | — | |
| Total distributions | | | (0.95 | ) | | | — | | | | (0.53 | ) | | | — | |
| Net asset value, end of period | | $ | 55.10 | | | $ | 36.82 | | | $ | 24.42 | | | $ | 22.02 | |
| Market value, end of period | | $ | 55.08 | | | $ | 36.85 | | | $ | 24.38 | | | $ | 21.92 | |
| Total Return at Net Asset Value(4) | | | 52.71 | %(3) | | | 50.77 | % | | | 13.43 | % | | | 10.10 | % |
| Total Return at Market Value(4) | | | 52.53 | %(3) | | | 51.15 | % | | | 13.83 | % | | | 9.60 | % |
Ratios/Supplemental Data:
| | | | | | | | | | | | | | | | |
| Net assets, end of period (000’s omitted) | | $ | 672,276 | | | $ | 68,109 | | | $ | 14,654 | | | $ | 12,111 | |
Ratio to average net assets of:
| | | | | | | | | | | | | | | | |
| Expenses | | | 0.75 | % | | | 0.75 | %(5) | | | 0.89 | % | | | 0.95 | %(5) |
| Net investment loss(6) | | | (0.18 | )% | | | (0.62 | )%(5) | | | (0.78 | )% | | | (0.65 | )%(5) |
| Portfolio turnover rate(7) | | | 68 | % | | | 52 | % | | | 86 | % | | | 103 | % |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| (1) | Commencement of operations. |
| (2) | Based on average daily shares outstanding. |
| (3) | The Adviser has reimbursed the Fund $13,773.94 for a procedural error. The impact was deemed immaterial to net realized and unrealized gain on investments and the Fund’s total return, representing less than $0.005 per share. |
| (4) | Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value. Market value total return is calculated assuming an initial investment made at the market value at the beginning of the period, reinvestment of all dividends, and distributions at market value during the period, and sale at the market value on the last day of the period. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Total return calculated for a period of less than one year is not annualized. |
| (6) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
| (7) | Portfolio turnover rate is not annualized and excludes the value of portfolio securities received or delivered as a result of in-kind creations or redemptions of the Fund’s capital shares. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Financial Highlights (concluded)
The 3D Printing ETF
For a share outstanding throughout each period presented.
| | | | | | |
| | | Year Ended
July 31, 2018 | | For the
Period Ended
July 31, 2017† | | For the Period
July 19,
2016(1) Through
August 31, 2016 |
Per Share Data:
| | | | | | | | | | | | |
| Net asset value, beginning of period | | $ | 25.52 | | | $ | 20.81 | | | $ | 20.00 | |
| Net investment loss(2) | | | (0.04 | ) | | | (0.03 | ) | | | 0.00 | (3) |
| Net realized and unrealized gain (loss) on investments | | | (0.73 | ) | | | 4.74 | | | | 0.81 | |
| Total gain (loss) from investment operations | | | (0.77 | ) | | | 4.71 | | | | 0.81 | |
| Distributions to shareholders: | | | | | | | | | | | | |
| Net investment income | | | — | | | | (0.00 | )(3) | | | — | |
| Realized gains | | | (0.53 | ) | | | — | | | | — | |
| Total distributions | | | (0.53 | ) | | | — | | | | — | |
| Net asset value, end of period | | $ | 24.22 | | | $ | 25.52 | | | $ | 20.81 | |
| Market value, end of period | | $ | 24.32 | | | $ | 25.52 | | | $ | 20.90 | |
| Total Return at Net Asset Value(4) | | | (3.05 | )% | | | 22.64 | % | | | 4.05 | % |
| Total Return at Market Value(4) | | | (2.64 | )% | | | 22.11 | % | | | 4.50 | % |
Ratios/Supplemental Data:
| | | | | | | | | | | | |
| Net assets, end of period (000’s omitted) | | $ | 47,220 | | | $ | 35,726 | | | $ | 6,243 | |
Ratio to average net assets of:
| | | | | | | | | | | | |
| Expenses | | | 0.66 | % | | | 0.66 | %(5) | | | 0.67 | %(5) |
| Net investment income (loss)(6) | | | (0.17 | )% | | | (0.14 | )%(5) | | | 0.19 | %(5) |
| Portfolio turnover rate(7) | | | 53 | % | | | 65 | % | | | — | % |
| † | The Trust changed its fiscal and tax reporting period from August 31 to July 31. |
| (1) | Commencement of operations. |
| (2) | Based on average daily shares outstanding. |
| (3) | Amount represents less than $0.005. |
| (4) | Net asset value total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of all dividends and distributions at net asset value during the period and redemption on the last day of the period at net asset value. Market value total return is calculated assuming an initial investment made at the market value at the beginning of the period, reinvestment of all dividends, and distributions at market value during the period, and sale at the market value on the last day of the period. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Total return calculated for a period of less than one year is not annualized. |
| (6) | Net investment income (loss) represents dividends received by the Fund from its underlying investments less expenses paid by the Fund during the period. |
| (7) | Portfolio turnover rate is not annualized and excludes the value of portfolio securities received or delivered as a result of in-kind creations or redemptions of the Fund’s capital shares. |
See accompanying Notes to Financial Statements.
TABLE OF CONTENTS
Notes to Financial Statements
July 31, 2018
1. Organization
ARK ETF Trust (“Trust”) is an open-end management investment company registered under the Investment Company Act of 1940, as amended (“1940 Act”). The Trust was organized as a Delaware statutory trust on June 7, 2013. The Trust consists of six (6) investment portfolios: ARK Genomic Revolution Multi-Sector ETF, ARK Industrial Innovation ETF, ARK Innovation ETF, ARK Israel Innovative Technology ETF, ARK Web x.0 ETF and The 3D Printing ETF (each, a “Fund” and collectively, “Funds”). Each Fund is classified as a non-diversified management investment company under the 1940 Act.
The investment objective of ARK Genomic Revolution Multi-Sector ETF, ARK Industrial Innovation ETF, ARK Innovation ETF and ARK Web x.0 ETF is long-term growth of capital. The ARK Israel Innovative Technology ETF seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the ARK Israel Innovation Index. The 3D Printing ETF seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Total 3D-Printing Index. There can be no assurance that the Funds will achieve their respective investment objectives.
The Trust changed its fiscal and tax reporting period from August 31 to July 31.
2. Significant Accounting Policies
These financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which require management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amount of increase and decrease in net assets from operations during the fiscal period. Actual amounts could differ from these estimates. The Trust is an investment company and follows the investment company accounting standards and reporting guidance under Financial Accounting Standards Board (FASB) Accounting Standard Codification (“ASC”) Topic 946, “Financial Services — Investment Companies”. The following summarizes the significant accounting policies of the Funds:
Investment Valuation
The values of each Fund’s securities are based on such securities’ closing prices on the principal market on which the securities are traded. Such valuations would typically be categorized as Level 1 in the fair value hierarchy. If a security’s market price is not readily available or does not otherwise accurately reflect the market value of such security, the security will be fair valued by ARK Investment Management LLC (“Adviser”) in accordance with the Trust’s valuation policies and procedures that were approved by the Board of Trustees of the Trust (“Board”). Each Fund may use fair value pricing in a variety of circumstances, including but not limited to, situations when the value of a Fund’s security has been materially affected by events occurring after the close of the market on which such security is principally traded (such as a corporate action or other news that may materially affect the price of such security) or trading in such security has been suspended or halted. Such valuations would typically be categorized as Level 2 or Level 3 in the fair value hierarchy. Fair value pricing involves subjective judgments and it is possible that a fair value determination for a security could be materially different than the value that could be realized upon the sale of such security.
Investment Transactions
Investment transactions are accounted for on the trade date. Realized gains and losses on sales of investment securities are calculated using the identified cost method. Dividend income is recognized on the ex-dividend date, except for certain foreign dividends that may be recorded as soon as such information becomes available. Interest income and expenses are recognized on the accrual basis.
Dividend Distributions
Distributions to shareholders are recorded on the ex-dividend date and are determined in accordance with federal income tax regulations, which may differ from U.S. GAAP. Each Fund distributes all or substantially all of its net investment income to shareholders in the form of dividends.
Currency Translation
Assets and liabilities, including investment securities, denominated in currencies other than U.S. dollars are translated into U.S. dollars at the exchange rates supplied by one or more pricing vendors on the valuation date. Purchases and sales of investment securities and income and expenses are translated into U.S. dollars at the exchange rates on the dates of such transactions.
The effects of changes in exchange rates on investment securities are included with the net realized gain or loss and net unrealized appreciation or depreciation on investments in each Fund’s statement of operations. The realized gain or loss and unrealized appreciation or depreciation resulting from all other transactions denominated in currencies other than U.S. dollars are disclosed separately.
TABLE OF CONTENTS
Notes to Financial Statements (continued)
July 31, 2018
3. Management and Other Agreements
Management
Effective June 1, 2016, the ARK Genomic Revolution Multi-Sector ETF, ARK Industrial Innovation ETF, ARK Innovation ETF and ARK Web x.0 ETF each pay the Adviser a fee calculated daily and payable monthly at an annual rate (stated as a percentage of the average daily net assets of the Fund) of 0.75% (“Management Fee”) in return for providing investment management and supervisory services under a comprehensive structure. The 3D Printing ETF pays the Adviser a Management Fee of 0.65% in return for providing investment management and supervisory services under a comprehensive structure. The ARK Israel Innovative Technology ETF pays the Adviser a Management Fee of 0.48% in return for providing investment management and supervisory services under a comprehensive structure. Prior to June 1, 2016, the ARK Genomic Revolution Multi-Sector ETF, ARK Industrial Innovation ETF, ARK Innovation ETF and ARK Web x.0 ETF each paid an annualized rate of 0.95%. Subject to the supervision of the Board, the Adviser provides investment management services to each Fund and provides, or causes to be furnished, all supervisory and other services reasonably necessary for the operation of each Fund and also bears the costs of various third-party services required by the Funds, including administration, certain custody, audit, legal, transfer agency, and printing costs. In addition to the Management Fee, each Fund bears other fees and expenses, such as taxes and governmental fees, brokerage fees, commissions and other transaction expenses, certain foreign custodial fees and expenses, costs of borrowing money, including interest expenses, and extraordinary expenses (such as litigation and indemnification expenses).
Administrator, Custodian, Transfer Agent and Accounting Agent
The Bank of New York Mellon is the administrator for the Funds, the custodian of the Funds’ assets and provides transfer agency, fund accounting and various administrative services to the Funds (in each capacity, “Administrator,” “Custodian,” “Transfer Agent” or “Accounting Agent”). The Bank of New York Mellon is a subsidiary of The Bank of New York Mellon Corporation, a financial holding company.
Distribution
Foreside Fund Services, LLC serves as the Funds’ distributor (“Distributor”). The Trust has adopted a distribution and service plan (“Rule 12b-1 Plan”) pursuant to Rule 12b-1 under the 1940 Act. Under the Rule 12b-1 Plan, each Fund is authorized to pay distribution fees in connection with the sale and distribution of its shares and pay service fees in connection with the provision of ongoing services to shareholders. To date, the Rule 12b-1 Plan has not been implemented for the Funds and there is no current intention to implement the Rule 12b-1 Plan.
Other Service Providers
Foreside Fund Officer Services, LLC (“FFOS”), an affiliate of the Distributor, provided a Treasurer & Chief Financial Officer (CFO) to the Trust. Neither the Distributor, FFOS nor any of their officers or employees who serve as an officer of the Trust, has any role in determining the investment policies of, or which securities are to be purchased or sold by, the Trust or its Funds. Effective June 2018, William C. Cox was re-elected to the Treasurer & CFO position.
Board of Trustees
Effective January 1, 2018, each Independent Trustee was paid quarterly in arrears a $37,000 annual fee for services provided as a Trustee of the Trust, plus out-of-pocket expenses related to attendance at Board and Committee Meetings. An Independent Trustee who served as the Chair of the Board or the Audit Committee also received an additional annual fee of $15,000 and $10,000, respectively for such services. Prior to this, each Independent Trustee was paid quarterly in arrears a $20,000 annual fee, out-of-pocket expenses and $5,000 each for the Chair of the Board or the Audit Committee.
4. Creation and Redemption Transactions
As of July 31, 2018, there were an unlimited number of shares of beneficial interest without par value authorized by the Trust. Individual shares of a Fund may only be purchased and sold at market prices on a national securities exchange through a broker-dealer. Such transactions may be subject to customary commission rates imposed by the broker-dealer, and market prices for a Fund’s shares may be at, above or below its net asset value (“NAV”) depending on the premium or discount at which the Fund’s shares trade.
Each Fund issues and redeems shares at its NAV only in a large specified number of shares each called a “Creation Unit,” or multiples thereof, and only with “authorized participants” who have entered into contractual arrangements with the Distributor. A Creation Unit consists of 50,000 shares (25,000 shares with respect to the ARK Israel Innovative Technology ETF). Except when aggregated in Creation Units, shares of each Fund are not redeemable. Transactions in shares for each Fund are disclosed in detail in the Statements of Changes in Net Assets. The consideration for a purchase of Creation Units generally consists of the in-kind deposit of specified securities and an amount of cash or, as
TABLE OF CONTENTS
Notes to Financial Statements (continued)
July 31, 2018
permitted or required by a Fund, of cash. A fixed transaction fee is imposed on each creation and redemption transaction. In addition, a variable charge for certain creation and redemption transactions will be imposed.
5. Investment Transactions
The cost of purchases and the proceeds from sales of investment securities (excluding in-kind subscriptions and redemptions and short-term investments) for the year ended July 31, 2018 were as follows:
| | | | |
| Fund | | Purchases | | Sales |
| ARK Genomic Revolution Multi-Sector ETF | | $ | 78,621,037 | | | $ | 80,068,996 | |
| ARK Industrial Innovation ETF | | | 68,305,464 | | | | 69,356,950 | |
| ARK Innovation ETF | | | 489,529,260 | | | | 470,696,544 | |
| ARK Israel Innovative Technology ETF | | | 7,622,649 | | | | 7,498,930 | |
| ARK Web x.0 ETF | | | 235,824,248 | | | | 223,807,330 | |
| The 3D Printing ETF | | | 24,048,477 | | | | 25,276,716 | |
For the year ended July 31, 2018, the cost of in-kind subscriptions and the proceeds from in-kind redemptions were as follows:
| | | | |
| | | In-Kind |
| Fund | | Subscriptions | | Redemptions |
| ARK Genomic Revolution Multi-Sector ETF | | $ | 189,958,891 | | | $ | — | |
| ARK Industrial Innovation ETF | | | 90,957,562 | | | | 16,440,383 | |
| ARK Innovation ETF | | | 1,013,475,599 | | | | 77,201,151 | |
| ARK Israel Innovative Technology ETF | | | 23,617,051 | | | | 2,036,729 | |
| ARK Web x.0 ETF | | | 584,970,387 | | | | 77,698,475 | |
| The 3D Printing ETF | | | 16,313,107 | | | | 2,515,707 | |
6. Federal Income Tax
Each Fund intends to qualify as a “regulated investment company” under Subchapter M of the Internal Revenue Code of 1986, as amended. If so qualified, a Fund will not be subject to Federal income tax to the extent it distributes substantially all of its net investment income and net capital gains to its shareholders. Accounting for Uncertainty in Income Taxes provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements, and requires the evaluation of tax positions taken or expected to be taken in the course of preparing a Fund’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax positions not deemed to meet the more-than-likely-than-not threshold would be recorded as a tax benefit or expense in the current year. Interest and penalty related to income taxes would be recorded as income tax expense. Management of the Funds is required to analyze all open tax years (2015 – 2017), as defined by IRS statute of limitations, for all major jurisdictions, including federal tax authorities and certain state tax authorities. As of July 31, 2018, the Funds did not have a liability for any unrecognized tax benefits. The Funds have no examination in progress and are not aware of any tax positions for which it is reasonably possible that the amounts of unrecognized tax benefits will significantly change in the next twelve months.
At July 31, 2018, the approximate cost of investments and net unrealized appreciation (depreciation) for federal income tax purposes was as follows:
| | | | | | | | |
| Fund | | Cost | | Gross
Unrealized
Appreciation | | Gross
Unrealized
Depreciation | | Net Unrealized
Appreciation
(Depreciation) |
| ARK Genomic Revolution Multi-Sector ETF | | $ | 217,505,278 | | | $ | 21,645,135 | | | $ | (7,048,823 | ) | | $ | 14,596,312 | |
| ARK Industrial Innovation ETF | | | 141,407,792 | | | | 20,362,195 | | | | (6,323,121 | ) | | | 14,039,074 | |
| ARK Innovation ETF | | | 1,099,112,381 | | | | 108,825,955 | | | | (36,414,856 | ) | | | 72,411,099 | |
| ARK Israel Innovative Technology ETF | | | 21,866,167 | | | | 2,127,948 | | | | (2,088,868 | ) | | | 39,080 | |
| ARK Web x.0 ETF | | | 656,267,523 | | | | 37,618,342 | | | | (21,099,009 | ) | | | 16,519,333 | |
| The 3D Printing ETF | | | 47,070,267 | | | | 5,398,217 | | | | (5,375,085 | ) | | | 23,132 | |
The differences between book-basis and tax-basis components of net assets are primarily attributable to tax deferral of losses on wash sales, non-REIT income and basis adjustments, grantor trust adjustments, and undistributed short-term capital gains treated as ordinary income for tax purposes.
TABLE OF CONTENTS
Notes to Financial Statements (continued)
July 31, 2018
At July 31, 2018, the components of distributable earnings/loss on a tax basis were as follows:
| | | | | | | | | | |
| Fund | | Undistributed
Income | | Undistributed
Long-term
Capital Gains | | Accumulated
Capital
Gains/(Losses) | | Net
Unrealized
Appreciation
(Depreciation) | | Total Earnings
(Losses) |
| ARK Genomic Revolution Multi-Sector ETF | | $ | 2,072,454 | | | $ | 2,493,590 | | | $ | — | | | $ | 14,596,312 | | | $ | 19,162,356 | |
| ARK Industrial Innovation ETF | | | 978,340 | | | | 1,573,065 | | | | — | | | | 14,039,074 | | | | 16,590,479 | |
| ARK Innovation ETF | | | 22,941,162 | | | | 1,107,324 | | | | — | | | | 72,411,099 | | | | 96,459,585 | |
| ARK Israel Innovative Technology ETF | | | 529,015 | | | | — | | | | (608,779 | ) | | | 39,080 | | | | (40,684 | ) |
| ARK Web x.0 ETF | | | 40,309,880 | | | | 5,386,291 | | | | — | | | | 16,519,333 | | | | 62,215,504 | |
| The 3D Printing ETF | | | 292,689 | | | | — | | | | (797,732 | ) | | | 22,396 | | | | (482,647 | ) |
At July 31, 2018, the effect of permanent book/tax reclassifications resulted in increase/(decrease) to the components of net assets as follows:
| | | | | | |
| Fund | | Undistributed
Net Investment
Income | | Accumulated
Net Realized
Gains/(Losses) | | Paid-in Capital |
| ARK Genomic Revolution Multi-Sector ETF | | $ | 568,916 | | | $ | (568,916 | ) | | $ | — | |
| ARK Industrial Innovation ETF | | | 399,617 | | | | (7,913,868 | ) | | | 7,514,251 | |
| ARK Innovation ETF | | | 4,232,851 | | | | (36,383,520 | ) | | | 32,150,669 | |
| ARK Israel Innovative Technology ETF | | | 347,193 | | | | (576,146 | ) | | | 228,953 | |
| ARK Web x.0 ETF | | | 2,763,686 | | | | (31,450,999 | ) | | | 28,687,313 | |
| The 3D Printing ETF | | | 77,918 | | | | (528,517 | ) | | | 450,599 | |
The tax character of distributions paid during the years indicated was as follows:
| | | | | | | | |
| | | Period Ended July 31, 2018 | | Period Ended July 31, 2017 |
| Fund | | Ordinary
Income* | | Long-Term
Capital Gain | | Ordinary
Income* | | Long-Term
Capital Gain |
| ARK Genomic Revolution Multi-Sector ETF | | $ | 415,312 | | | $ | 290,860 | | | $ | — | | | $ | — | |
| ARK Industrial Innovation ETF | | | 1,072,610 | | | | 703,605 | | | | — | | | | — | |
| ARK Innovation ETF | | | 4,463,463 | | | | 485,779 | | | | — | | | | — | |
| ARK Israel Innovative Technology ETF | | | — | | | | — | | | | — | | | | — | |
| ARK Web x.0 ETF | | | 2,903,724 | | | | 1,958,185 | | | | — | | | | — | |
| The 3D Printing ETF | | | 820,636 | | | | 180,455 | | | | 759 | | | | — | |
* For tax purposes short-term capital gain distributions are considered ordinary income distributions.
Under current tax regulations, capital losses on securities transactions realized after October 31 (“Post-October Losses”) may be deferred and treated as occurring on the first business day of the following fiscal year. For the period ended July 31, 2018, the Funds incurred and elected to defer to August 1, 2018 Post-October Losses and ordinary income losses as follows:
| | | | |
| Fund | | Late Year
Ordinary
Deferral | | Capital
Post-October
Loss |
| ARK Genomic Revolution Multi-Sector ETF | | $ | — | | | $ | — | |
| ARK Industrial Innovation ETF | | | — | | | | — | |
| ARK Innovation ETF | | | — | | | | — | |
| ARK Israel Innovative Technology ETF | | | — | | | | — | |
| ARK Web x.0 ETF | | | — | | | | — | |
| The 3D Printing ETF | | | — | | | | 797,732 | |
TABLE OF CONTENTS
Notes to Financial Statements (concluded)
July 31, 2018
At July 31, 2018, for Federal income tax purposes, the Funds have capital loss carryforwards available as shown in the table below, to the extent provided by regulations, to offset future capital gains for an unlimited period. To the extent that these capital loss carryforwards are used to offset future capital gains, it is probable that the capital gains so offset will not be distributed to shareholders.
| | | | | | |
| | | Short-Term | | Long-Term | | Total Amount |
| ARK Genomic Revolution Multi-Sector ETF | | $ | — | | | $ | — | | | $ | — | |
| ARK Industrial Innovation ETF | | | — | | | | — | | | | — | |
| ARK Innovation ETF | | | — | | | | — | | | | — | |
| ARK Israel Innovative Technology ETF | | | 608,779 | | | | — | | | | 608,779 | |
| ARK Web x.0 ETF | | | — | | | | — | | | | — | |
| The 3D Printing ETF | | | — | | | | — | | | | — | |
7. Indemnification Obligations
The Funds have a variety of indemnification obligations under contracts with their service providers. The Funds’ maximum exposure under these arrangements is unknown. However, the Funds have not had prior claims or losses pursuant to these contracts and expect the risk of loss to be remote.
8. Investment Concentration
Concentration Risk: The ARK Genomic Revolution Multi-Sector ETF will be concentrated in issuers having their principal business activities in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. The ARK Industrial Innovation ETF will be concentrated in issuers having their principal business activities in groups of industries in the industrials and information technology sectors, although it will not concentrate in any specific industry. The ARK Web x.0 ETF will be concentrated in issuers having their principal business activities in the Internet information provider and catalog and mail order house industry. The 3D Printing ETF may invest 25% or more of the value of its net assets in securities of issuers in any one industry or group of industries if the index that the Fund replicates concentrates in an industry or group of industries. This concentration limit does not apply to securities issued or guaranteed by the U.S. Government, its agencies or instrumentalities. The ARK Innovation ETF will not be concentrated in any industry.
As of July 31, 2018, the ARK Genomic Revolution Multi-Sector ETF had more than 25% of its assets invested in the biotechnology industry and the ARK Web x.0 ETF had more than 25% of its assets invested in the Internet software & services industry. To the extent a Fund’s holdings are concentrated in a particular industry or group of industries, adverse market conditions affecting those industries may have a more significant impact on the Fund than they would on a Fund investing in a broader range of securities and the value of the Fund’s shares may fluctuate more than shares of a fund investing in a broader range of securities.
The Funds’ prospectuses contain additional information regarding the risks associated with an investment in a Fund.
9. Related Party
In January 2018, William C. Cox resigned from Foreside Financial Group. In his place, Joshua G. Hunter served as Treasurer & CFO of the Trust. In June 2018, William was subsequently hired as an employee of ARK Investment Management, LLC and resumed his responsibilities as Treasurer & CFO of the Trust.
10. Subsequent Events
Subsequent events occurring after the date of this Report have been evaluated for potential impact to this Report through the date the Report was issued, and it has been determined that no events have occurred that require disclosure.
TABLE OF CONTENTS
Report of Independent Registered Public Accounting Firm
To the Board of Trustees and Shareholders of
ARK ETF Trust
Opinion on the Financial Statements
We have audited the accompanying statements of assets and liabilities of ARK Genomic Revolution Multi-Sector ETF, ARK Industrial Innovation ETF, ARK Innovation ETF, ARK Israel Innovative Technology ETF, ARK Web x.0 ETF, and The 3D Printing ETF (the “Funds”), each a series of ARK ETF Trust (the “Trust”), including the schedules of investments, as of July 31, 2018, and with respect to the ARK Industrial Innovation ETF and ARK Web x.0 ETF, the related statements of operations for the year then ended, the statements of changes in net assets for the year then ended, for the eleven months ended July 31, 2017, and for the year ended August 31, 2016, and financial highlights for the year then ended, for the eleven months ended July 31, 2017, for the year ended August 31, 2016 and the period September 30, 2014 (commencement of operations) through August 31, 2015, with respect to the ARK Genomic Revolution Multi-Sector ETF and ARK Innovation ETF, the related statements of operations for the year then ended, the statements of changes in net assets for the year then ended, for the eleven months ended July 31, 2017, and for the year ended August 31, 2016, and financial highlights for the year then ended, for the eleven months ended July 31, 2017, for the year ended August 31, 2016, and the period October 31, 2014 (commencement of operations) through August 31, 2015, with respect to The 3D Printing ETF, the related statement of operations for the year then ended, the statements of changes in net assets and financial highlights for the year then ended, for the eleven months ended July 31, 2017 and for period July 19, 2016 (commencement of operations) through August 31, 2016, and with respect to ARK Israel Innovative Technology ETF, the related statement of operations, statement of changes in net assets and financial highlights for the period December 5, 2017 (commencement of operations) through July 31, 2018, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Funds as of July 31, 2018, the results of their operations, the changes in their net assets, and their financial highlights for the periods indicated therein, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Funds’ management. Our responsibility is to express an opinion on the Funds’ financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We have served as the auditor of one or more of the Funds since 2014.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Funds are not required to have, nor were we engaged to perform, an audit of the Funds’ internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our procedures included confirmation of securities owned as of July 31, 2018 by correspondence with the custodian and brokers, and other appropriate auditing procedures. We believe that our audits provide a reasonable basis for our opinion.
TAIT, WELLER & BAKER LLP
Philadelphia, Pennsylvania
September 28, 2018
TABLE OF CONTENTS
Supplemental Information (Unaudited)
Quarterly Portfolio Schedule. The ARK ETF Trust files with the Securities and Exchange Commission on Form N-Q the complete schedule of portfolio holdings for each ARK ETF for the first and third quarters of each fiscal year. The ARK ETF Trust’s Forms N-Q are available on the Securities and Exchange Commission’s website at www.sec.gov. The ARK ETF Trust’s Forms N-Q may be reviewed and copied at the Securities and Exchange Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 1-800-SEC-0330. The most recent Form N-Q is available without charge, upon request, by calling 1-212-426-7040. In addition, each ARK ETF’s current portfolio holdings are updated daily and are available on our website, www.ark-funds.com.
Proxy Voting Policies and Procedures. A description of ARK Investment Management LLC’s proxy voting policies and procedures, which are applicable to the ARK ETFs, is available without charge, upon request, by calling 1-212-426-7040 collect or visiting our website at www.ark-funds.com or the Securities and Exchange Commission’s website at www.sec.gov.
Proxy Voting Record. The ARK ETFs file with the Securities and Exchange Commission their proxy voting records on Form N-PX for each 12 month period ending June 30. Form N-PX must be filed each year by August 31. The most recent Form N-PX or voting record information is available without charge, upon request, by calling 1-212-426-7040 collect or visiting the Securities and Exchange Commission’s website at www.sec.gov.
Premium/Discount Information. Information about the difference between daily market prices on the secondary market for shares of each ARK ETF and the ARK ETF’s net asset value can be found on our website, www.ark-funds.com.
Tax Information
Form 1099-DIV and other year-end tax information provide shareholders with actual calendar year amounts that should be included in their tax returns. Shareholders should consult their tax advisors. Each Fund designates the following amounts or, if subsequently determined to be different, the maximum allowable for its year ended July 31, 2018.
| | | | |
| | | Qualified
Dividend Income* | | Dividends
Received Deduction* |
| ARK Genomic Revolution Multi-Sector ETF | | | 3 | % | | | 3 | % |
| ARK Industrial Innovation ETF | | | 34 | % | | | 22 | % |
| ARK Innovation ETF | | | 3 | % | | | 2 | % |
| ARK Israel Innovative Technology ETF | | | 0 | % | | | 0 | % |
| ARK Web x.0 ETF | | | 3 | % | | | 1 | % |
| The 3D Printing ETF | | | 28 | % | | | 19 | % |
| * | The above percentage is based on ordinary income dividends paid to shareholders during each Fund’s fiscal year. |
TABLE OF CONTENTS
Board Approval of Management Agreements (Unaudited)
Annual Review and Approval of Trust Contracts
Under section 15(c) of the Investment Company Act of 1940 (“1940 Act”), the ARK ETF Trust’s (“Trust”) Board of Trustees (“Trustees” or “Board”), including a majority of Trustees who are not “interested persons” of the Trust (as that term is defined in the 1940 Act) (“Independent Trustees”), is required annually to consider and approve the continuation of (i) the Supervision Agreement between the Trust and ARK Investment Management, LLC (“ARK”) on behalf of each series of the Trust (each, a “Fund” and, collectively, “Funds”); and (ii) the Investment Advisory Agreement between the Trust and ARK (collectively, “Management Agreements”) on behalf of each Fund. In advance of the quarterly Board meeting held on June 25, 2018 (“Meeting”), counsel to the Independent Trustees (“Independent Trustee Counsel”), sent a letter to ARK (“Request Letter”), on the behalf of the Independent Trustees, requesting ARK to furnish the Independent Trustees with such information, set forth in the Request Letter, that the Independent Trustees believed was reasonably necessary to enable them to evaluate whether to approve the continuation of the Management Agreements. In response to the Request Letter, ARK provided a full and detailed response letter (including exhibits) (“Response Letter”) to the Independent Trustees. Additionally, based on their review of the Response Letter, the Independent Trustees sent a follow-up letter (“Follow-up Request”) requesting that ARK address each item set forth in the Follow-up Request prior to or at the Meeting.
Prior to the Meeting, the Independent Trustees had an opportunity to review the detailed information in the Response Letter and to meet with Independent Trustee Counsel to discuss the Response Letter and prepare the Follow-up Request. Independent Trustee Counsel also provided a memorandum to the Independent Trustees outlining the Independent Trustees’ various duties and responsibilities in connection with their annual review and consideration of the Trust’s Management Agreements. Additionally, the Independent Trustees met in Executive Session with ARK’s senior management regarding, among other things, the Response Letter, and discussed with ARK’s senior management salient information contained in the Response Letter. Prior to the Meeting, ARK provided the Independent Trustees with additional information and detailed responses (“Supplemental Response”) to the Follow-up Request in connection with the consideration and approval by the Trustees of the continuation of the Management Agreements. During the Meeting, ARK and the Board also discussed any outstanding items listed in the Follow-up Request that ARK did not address in its Supplemental Response.
After the presentation of relevant information by ARK’s senior management and extensive discussions at the Meeting, and following an additional Executive Session of the Independent Trustees with Independent Trustee Counsel, the Trustees, including the Independent Trustees voting separately, unanimously approved the continuance of the Management Agreements on behalf of the Funds. The Trustees’ approval of the continuance of the Management Agreements was based on, among other things, a review of qualitative and quantitative information provided by ARK, including the Response Letter and the Supplemental Response. The Independent Trustees noted that the Response Letter and Supplemental Response were sufficiently responsive to the Request Letter and Follow-up Request to permit the Board to evaluate and approve the continuation of the Management Agreements. The Board also considered other information, provided to the Board during the year, as part of its robust evaluation process. The determination made by all of the Trustees to approve the continuation of the Management Agreements was made on the basis of each Trustee’s business judgment after considering all of the information presented to them. Individual Trustees may have given different weights to certain factors and assigned various degrees of materiality to information received in connection with the contract review process. In approving the continuation of the Management Agreements for each Fund, the following factors were considered by the Trustees, and no one factor was determinative:
(a) The nature, extent and quality of the services provided by ARK to the Funds under the Management Agreements. Based on ARK’s senior management’s representations, the Trustees considered at the Meeting the nature, extent and quality of the services that ARK provides and will continue to provide under the Management Agreements, including: (i) the qualifications of the portfolio manager, analysts and other key personnel of ARK who provide and will continue to provide the supervisory and advisory services to the Trust and (ii) the terms of the Management Agreements. With respect to the terms of the Management Agreements, ARK’s senior management discussed the duties and responsibilities of ARK to, among other things: (i) provide or cause to be furnished all supervisory and other services reasonably necessary for the operation of the Trust, including investment advisory services, administrative services, distribution services, transfer agency services, custodial services, audit services, legal services, and printing costs; (ii) manage the investment operations of the Funds and the composition of each Fund’s assets, including the purchase, retention and disposition of securities and assets held by the Funds; (iii) prepare and provide quarterly and other reports to the Trustees concerning ARK’s provision of services to the Funds; (iv) vote proxies, exercise consents, and exercise all other rights pertaining to securities and assets held by each Fund; (v) select broker-dealers to execute portfolio transactions for each Fund, as appropriate; (vi) assist in the preparation and filing of reports and proxy statements (if any) to the shareholders of each Fund and assist in the periodic updating of the registration statement, prospectus, statement of additional information, and other reports and documents for the Funds required to be filed by the Trust with the U.S. Securities and Exchange Commission (“SEC”) and other governmental bodies; (vii) monitor anticipated purchases and redemptions of Fund shares (including creation units) by shareholders and new investors; and
TABLE OF CONTENTS
Board Approval of Management Agreements (Unaudited) (continued)
(viii) provide information and assistance as reasonably requested by the other service providers of the Trust. The Trustees also considered the organizational structure of ARK, the quality of ARK’s investment, administrative, operations, and legal personnel and ARK’s management of the operations of the Funds.
Based on these and other factors, the Trustees concluded that the nature, extent and quality of the supervisory and investment advisory services that would continue to be provided to the Funds by ARK were satisfactory and supported the decision of the Trustees to approve the continuation of the Management Agreements with respect to each Fund.
(b) The investment performance of the Funds relative to comparable funds and accounts managed by ARK and other investment advisers. In advance of the Meeting and in the Response Letter, ARK’s senior management provided the Trustees with information concerning the performance of each of the Funds and comparable funds or accounts (if any) managed by ARK and comparable funds (including ETFs) or accounts managed by other investment advisers measured against the performance of appropriate, recognized market indices for the one-year, three-year and since inception periods ended March 31, 2018, as applicable. The Trustees considered such information and requested additional information concerning the performance of the Funds, which information was provided to the Trustees during the Meeting and in the Supplemental Response. Additionally, at the Meeting the Trustees asked ARK’s senior management additional questions regarding the performance of the Funds, which were answered to their satisfaction.
Based upon their review of the investment performance of each Fund and ARK’s senior management’s discussion of the investment performance of the Funds, the Trustees concluded that each Fund’s overall performance was satisfactory relative to the performance of comparable funds and relevant market indices.
(c) A comparison of the current annual Advisory Fees of the Funds with those of other funds and other proprietary, private or other pooled funds managed by ARK with comparable investment strategies. In considering this factor, the Trustees considered a comparison of the advisory fees paid by the Funds with those paid by comparable actively-managed funds and ETFs and passively-managed ETFs. The Board noted that the advisory fee paid by each actively-managed Fund was at or below the advisory fees of most of the actively-managed funds and ETFs in the peer comparison group and that the advisory fee paid by each passively-managed Fund was below the advisory fees of the passively-managed ETFs in the peer comparison group. The Board also considered fee information for comparable funds and accounts managed by ARK. The Board noted that the fees paid by certain funds and accounts managed by ARK are the same as the advisory fees paid by the Funds and that in instances where comparable funds or accounts managed by ARK paid lower fees than the Funds, ARK generally provides these clients with fewer services than it provides to the Funds. The Board also reviewed the appropriateness of the universe of funds to whose investment advisory fees the advisory fees of the Funds were compared, and took into consideration ARK’s statement that there are a limited number of funds and ETFs that are comparable to the Funds.
Based upon their review of the comparative fee data and the other factors considered, the Trustees concluded that the Advisory Fee paid by each Fund was reasonable in light of the services received by the Fund.
(d) A comparison of the annual Management Fees (under the Supervision Agreement) and the annual Advisory Fees (under the Investment Advisory Agreement) for the Funds with the fees of comparable funds and other accounts managed by other advisers. In considering this factor, the Trustees noted that in 2017 ARK voluntarily reduced (i) its annual Management Fees for the actively-managed Funds under the Supervision Agreement from 0.95% to 0.75% of the average daily net assets of each Fund; and (ii) its annual Advisory Fees for the actively-managed Funds under the Investment Advisory Agreement from 0.60% to 0.55% of the average daily net assets of each Fund. During the Meeting, ARK's senior management discussed the effect the reduced Management Fees and Advisory Fees had on the actively-managed Funds, and the favorable impact the fee reductions had on the performance of the actively-managed Funds.
In the Board's review of this factor, the Trustees considered a comparison of the net expense ratios of the Funds with the net expense ratios of (i) similar actively-managed equity ETFs that ARK had identified as the most comparable to the Funds; and (ii) passively-managed thematic equity ETFs that ARK had identified as the most comparable to the Funds. The Trustees noted that the actively-managed Funds' net expense ratios generally were in line with those of comparable actively-managed ETFs and that the passively-managed Funds’ net expense ratios generally were in line with those of comparable passively-managed ETFs. The Trustees took into account the statement by ARK’s senior management that there are a limited number of ETFs that are comparable to the Funds and management's discussion of any differences between the net expense ratios of comparable ETFs and those of the Funds.
The Trustees also took into consideration ARK’s view that the unitary structure of the Management Fees (which includes, among other things, the Advisory Fees) of the Funds would continue to be easy to understand by investors and would provide a level of predictability with respect to the total expense ratios for the Funds. ARK’s senior management reaffirmed to the Trustees that (i) the nature, level and quality of
TABLE OF CONTENTS
Board Approval of Management Agreements (Unaudited) (concluded)
services under the Supervision Agreement and the Investment Advisory Agreement did not change as a result of the fee reductions; (ii) ARK still bears most of the ordinary fees and expenses of each Fund despite the reduction in the Management Fees and Advisory Fees, including the cost of various third-party services required by each Fund (e.g., investment advisory, administration, fund accounting, transfer agency, custody, audit, legal, and printing costs); and (iii) each Fund continues to bear certain other expenses not covered under the Supervision Agreement.
Based on the fee comparisons provided to the Board and other factors considered, the Trustees concluded that the net expense ratio of each Fund, which reflected both the Management Fee and Advisory Fee, was reasonable.
(e) The extent to which economies of scale may be realized as the Funds’ assets increase and whether fee levels would reflect economies of scale. In considering economies of scale with respect to the Funds, ARK’s senior management (i) reviewed with the Trustees the structure of the current Management Fees and Advisory Fees, (ii) the effect of the previously implemented reduction in the Management Fees and Advisory Fees, and (iii) noted that the unitary fee structure effectively acts as a cap on the fees and expenses (excluding certain specific investment-related and extraordinary fees and expenses) that are borne by the Funds. The Trustees noted that ARK still bears most of the ordinary fees and expenses of each Fund. The Trustees also noted that, although there currently are no breakpoints in any Fund’s Management Fees or Advisory Fees, if a Fund’s assets increase over time, the Fund might realize other economies of scale if assets increase proportionally more than certain other expenses.
Based on these considerations, the Trustees concluded that that adding breakpoints at specified levels to the Funds’ Management Fees and Advisory Fees was not appropriate at that time.
(f) The cost of the services provided and profits realized by ARK from the relationship with the Trust. The Trustees considered the fact that the fees and expenses of the Funds, which have been assumed and paid by ARK in accordance with the Management Agreements, have historically exceeded the fees received by ARK since the inception of each Fund. The Trustees took into account ARK’s projections regarding the future profitability of the Funds in view of their size and expense structure.
Based on the information provided to the Trustees, the Trustees concluded that the cost of the services provided to the Funds and the fees and expenses paid by ARK continued to exceed the fees received by ARK from the Funds.
(g) Benefits derived or to be derived by ARK and its Affiliates from their relationship with the Funds. The Trustees noted that ARK’s reputation as an asset manager has likely benefitted from the performance of the Funds and had the potential to aid ARK in gathering assets for its non-fund business operations. The Trustees also took into account that ARK’s affiliates were likely to benefit from the popularity and positive reception of the Funds. The Trustees also noted that an affiliate of ARK received compensation as a result of ARK’s relationship to the Funds.
The Board concluded that the nature and amount of any indirect benefits received by ARK and its affiliates from their relationship with the Funds are reasonable.
(h) Financial Resources of ARK. The Trustees then considered whether ARK was financially sound and had adequate resources to perform its obligations under the Management Agreements. The Trustees considered ARK’s senior management’s discussion of ARK’s financial condition and its access to sufficient capital to allow it to perform its ongoing contractual obligations to the Funds.
Based on the information provided to the Board, the Trustees concluded that ARK had sufficient financial resources necessary to continue to perform its obligations under the Management Agreements.
General Conclusion. After considering and weighing all of the above factors, the Board concluded that it would be in the best interest of each Fund and its shareholders to approve the continuation of the Management Agreements, which reflected the reduced Management Fees under the Supervisory Agreement and the reduced Advisory Fees under the Investment Advisory Agreement with respect to each actively-managed Fund. In addition, based on, on among other things, the Trustees’ thorough review and evaluation of the Response Letter and Supplemental Response that ARK provided to them in response to the Request Letter and Follow-up Request; the factors, issues, and conclusions described above; and the extensive discussions held among the Trustees and ARK’s senior management, the Board, with Independent Trustees voting separately, unanimously approved the continuation of the Management Agreements with respect to each Fund.
TABLE OF CONTENTS
Board of Trustees and Executive Officers (Unaudited)
Trustees and Executive Officers. Information about the Trustees and Executive Officers of the Trust as of July 31, 2018, including their business addresses, ages and principal occupations during the past five years, and other directorships of publicly traded companies or funds, is set forth in the table below.
Independent Trustees
| | | | | | | | |
| Name, Address(1) and Age | | Position(s)
Held with
the Trust | | Term of Office(2)
and Length of
Time Served | | Principal Occupation(s)
During Past Five Years | | Other Directorships
Held By Trustee
During Past Five Years |
| Scott R. Chichester, 48 | | Trustee | | Since June 30, 2014 | | Chief Financial Officer, Sterling Seal & Supply Inc. (since 2011); Director, President and Treasurer, Bayview Acquisition Corp (since 2010); CPA, Penda Aiken Inc. (2009 – 2011) (consultant); Founder and President, DirectPay USA LLC (since 2006) (payroll company); Chief Financial Officer, Ong Corporation (2002 – 2010) (technology company); Proprietor, Scott R. Chichester CPA (since 2001) (CPA firm).
| | Director of Bayview Acquisition Corp (since 2010); Trustee of Global X Funds (since 2008); Director of Sterling Seal & Supply Inc. (since 2011).
|
| Darlene T. DeRemer, 62 | | Trustee | | Since June 30, 2014 | | Managing Partner, Grail Partners LLC
(since 2005). | | Trustee, Member of Executive Committee and Chair of Investment and Endowment Committee of Syracuse University (since 2010); Interested Trustee, American Independence Funds (since 2015); Trustee, Risk X Investment Funds (since September 2016); Director, United Capital Financial Planners; Director, Hillcrest Asset Management.
|
| Robert G. Zack, 70 | | Trustee | | Since June 30, 2014 | | Adjunct Professor at the University of Virginia School of Law; Counsel, Dechert LLP
(2012 – 2014); Executive Vice President, OppenheimerFunds, Inc. (2004 – 2011); General Counsel, OppenheimerFunds, Inc. (2002 – 2010); Secretary and General Counsel, Oppenheimer Acquisition Corp. (2001 – 2011); Executive Vice President, General Counsel and Director, OFI Trust Co. (2001 – 2011); Vice President and Secretary, Oppenheimer funds (2002 – 2011).
| | Trustee of University of Virginia Law School Foundation (since 2011). |
| (1) | The address for each Trustee and officer is 155 West 19th Street, Fifth Floor, New York, NY 10011. |
| (2) | Each Trustee serves until resignation, death, retirement or removal. |
TABLE OF CONTENTS
Board of Trustees and Executive Officers (Unaudited) (concluded)
Interested Trustee
| | | | | | | | |
| Name, Address(1) and Age | | Position(s)
Held with
the Trust | | Term of Office(2)
and Length of
Time Served | | Principal Occupation(s)
During Past Five Years | | Other Directorships
Held By Trustee
During Past Five Years |
| Catherine D. Wood, 62 | | Chief Executive Officer, Chief Investment Officer and Trustee | | Since June 7, 2013 | | Managing Member, Founder and Chief Executive Officer, ARK Investment Management LLC (since 2013); President, ARK ETF Trust
(2014 – 2015); Senior Vice President and Chief Investment Officer of Thematic Portfolios,
AllianceBernstein L.P. (2009 – 2013). | | None. |
| (1) | The address for each Trustee and officer is 155 West 19th Street, Fifth Floor, New York, NY 10011. |
| (2) | Each Trustee serves until resignation, death, retirement or removal. |
Officer Information
| | | | | | |
| Officer’s Name, Address(1) and Age | | Position(s)
Held with
the Trust | | Term of Office(2)
and Length of
Time Served | | Principal Occupation(s)
During The Past Five Years |
| Catherine D. Wood, 62 | | Trustee, Chief Executive Officer and Chief Investment Officer | | Since 6/30/14 | | Managing Member, Founder and Chief Executive Officer, ARK Investment Management LLC (since 2013); President, ARK ETF Trust (2014 – 2015); Senior Vice President and Chief Investment Officer of Strategic Thematic Strategies, AllianceBernstein L.P. (2001 – 2013).
|
| William C. Cox, 52 | | Treasurer and Chief Financial Officer | | Since 6/30/14* | | Principal Financial Officer, Investment Products, ARK Investment Management LLC (since June 2018); Fund Principal Financial Officer, Foreside Financial Group, LLC (2013 – 2018); Vice President, State Street Corporation (1997 – 2012).
|
| Kellen Carter, 35 | | Chief Compliance Officer; Secretary; Chief Legal Officer | | Since 5/26/16
Since 5/26/16
Since 12/16/16 | | Chief Compliance Officer, Associate General Counsel (since April 2016), Interim General Counsel, ARK Investment Management LLC (2016 – 2018), Corporate Counsel, ARK Investment Management LLC (since July 2018); Management Consultant, Wealth and Asset Management Division Ernst & Young LLP (2014 – 2016); Attorney, Risk and Examinations Office, Division of Investment Management, United States Securities and Exchange Commission (2013 – 2014); Examiner, Division of Investment Management, United States Securities and Exchange Commission (2012 – 2013); Examiner, Office of Compliance, Inspections, and Examinations, United States Securities and Exchange Commission (2010 – 2012).
|
| Thomas G. Staudt, 30 | | President Vice President | | Since 12/16/16
03/27/15 – 12/16/16 | | Director of Product Development and Associate Operating Officer (2015 – 2016), Interim Chief Operating Officer, ARK Investment Management LLC (2016 – 2018), Chief Operating Officer, ARK Investment Management LLC (since April 2018); Associate Portfolio Manager, ARK Investment Management LLC (2014 – 2015); Account Executive, WILX (2010 – 2012). |
| (1) | The address for each officer is 155 West 19th Street, Fifth Floor, New York, NY 10011. |
| (2) | Officers are elected yearly by the Trustees. |
The Statement of Additional Information for the Trust includes additional information about the Trustees and is available, without charge, upon request, by calling 1-212-426-7040 collect or visiting our website at www.ark-funds.com.
| * | In January 2018, William C. Cox resigned from Foreside Financial Group. In his place, Joshua G. Hunter served as Treasurer & CFO of the Trust. In June 2018, William was subsequently hired as an employee of ARK Investment Management, LLC and resumed his responsibilities as Treasurer & CFO of the Trust. |
TABLE OF CONTENTS
(This page intentionally left blank.)
TABLE OF CONTENTS
General Information (Unaudited)
Investment Adviser
ARK Investment Management LLC
155 West 19th Street, Fifth Floor
New York, NY 10011
Administrator, Custodian, Transfer Agent, and Accounting Agent
The Bank of New York Mellon
101 Barclay Street
New York, NY 10286
Distributor
Foreside Fund Services, LLC
Three Canal Plaza, Suite 100
Portland, ME 04101
Independent Registered Public Accounting Firm
Tait, Weller & Baker LLP
1818 Market Street, Suite 2400
Philadelphia, PA 19103
TABLE OF CONTENTS
This report is submitted for the general information of the shareholders of each Fund. It is not authorized for distribution to prospective investors unless preceded or accompanied by an effective prospectus, which includes information regarding the Funds’ risks, objectives, fees and expenses, experience of their management, and other information.
ARK Invest | 155 West 19th Street 5th Floor, New York, NY 10011 | 212.426.7040 | info@ark-invest.com | ark-funds.com
Item 2. Code of Ethics.
| (a) | As of the end of the period covered by this report, the registrant has adopted a code of ethics that applies to the registrant’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, regardless of whether these individuals are employed by the registrant or a third party (“Code of Ethics”). |
(c) There have been no amendments, during the period covered by this report, to a provision of the code of ethics that applies to the registrant’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, regardless of whether these individuals are employed by the registrant or a third party, and that relates to any element of the code of ethics description.
| (d) | During the period covered by this report, the registrant did not grant any waivers, including an implicit waiver, from a provision of the Code of Ethics that relates to one or more of the items set forth in paragraph (b) of this Item’s instructions. |
| (f) | The Code of Ethics is attached hereto as Exhibit 12(a)(1). |
Item 3. Audit Committee Financial Expert.
The registrant’s board of trustees has determined that the registrant has at least one “audit committee financial expert” (as defined in Item 3 of Form N-CSR) serving on its audit committee. Scott R. Chichester is qualified to serve as an “audit committee financial expert” and is “independent” (as each term is defined in Item 3 of Form N-CSR).
Item 4. Principal Accountant Fees and Services.
Audit Fees
| (a) | The aggregate fees billed for professional services rendered by the principal accountant for the audit of the registrant's annual financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the fiscal years are $62,500 for July 31, 2017 and $84,000 for July 31, 2018. |
Audit-Related Fees
| (b) | The aggregate fees billed in each of the last two fiscal years for assurance and related services by the principal accountant that are reasonably related to the performance of the audit of the |
registrant's financial statements and are not reported under paragraph (a) of this Item are $0 for July 31, 2017 and $0 for July 31, 2018.
Tax Fees
| (c) | The aggregate fees billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning are $12,500 for July 31, 2017 and $21,000 for July 31, 2018. |
All Other Fees
| (d) | The aggregate fees billed in each of the last two fiscal years for products and services provided by the principal accountant, other than the services reported in paragraphs (a) through (c) of this Item are $0 for July 31, 2017 and $0 for July 31, 2018. |
| (e)(1) | The registrant’s audit committee (“Audit Committee”) has adopted an Audit and Non-Audit Services Pre-Approval Policy (“Pre-Approval Policy”) that applies to any and all engagements of the independent auditor to the registrant for audit, non-audit, tax or other services. Pursuant to the Pre-Approval Policy, the Audit Committee is required to pre-approve the audit services and permissible non-audit services proposed to be performed by the independent auditor for the registrant to assure that the independence of the auditor is not in any way compromised or impaired. In assessing whether a particular audit or non-audit service should be approved, the Audit Committee will take into account the ratio between the total amounts paid for audit, audit-related, tax and other services, based on historical patterns, with a view toward assuring that the level of fees paid for non-audit services as they relate to the fees paid for audit services does not compromise or impair the independence of the auditor. The Audit Committee may either grant general pre-approval of proposed services of the independent auditor through adoption of a list of authorized services together with a budget of expected costs for those services (“general pre-approval”), or specific pre-approval of services provided on a case-by-case basis (“specific pre-approval”). Unless particular services have received general pre-approval, those services will require specific pre-approval by the Audit Committee before any such services can be provided by the independent auditor. The annual audit services engagement terms and fees for the independent auditor for the registrant require specific pre-approval of the Audit Committee. The Audit Committee may grant general pre-approval for (i) other audit services, which are those services that only the independent auditor reasonably can provide, (ii) audit related services, (iii) those tax services that have historically been provided by the independent auditor, and (iv) those permissible non-audit services classified as “all other” services that the Audit Committee believes are routine and recurring services. The Audit Committee from time to time may delegate either general or specific pre-approval authority to one or more of its members. Any member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting. The Audit Committee has not delegated either general or specific pre-approval authority to one or more of its members. |
| (e)(2) | The percentage of services described in each of paragraphs (b) through (d) of this Item that were approved by the audit committee pursuant to paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X are as follows: |
(b) N/A
(c) N/A
(d) N/A
| (f) | The percentage of hours expended on the principal accountant's engagement to audit the registrant's financial statements for the most recent fiscal year that were attributed to work performed by persons other than the principal accountant's full-time, permanent employees was less than fifty percent. |
| (g) | The aggregate non-audit fees billed by the registrant's accountant for services rendered to the registrant, and rendered to the registrant's investment adviser (not including any sub-adviser whose role is primarily portfolio management and is subcontracted with or overseen by another investment adviser), and any entity controlling, controlled by, or under common control with the adviser that provides ongoing services to the registrant for the registrant’s fiscal year ended July 31, 2017 were $0 and for July 31, 2018 were $0. |
Item 5. Audit Committee of Listed Registrants.
Not applicable.
Item 6. Investments.
| (a) | Schedule of Investments in securities of unaffiliated issuers as of the close of the reporting period is included as part of the report to shareholders filed under Item 1 of this form. |
Item 7. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.
Not applicable.
Item 8. Portfolio Managers of Closed-End Management Investment Companies.
Not applicable.
Item 9. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.
Not applicable.
Item 10. Submission of Matters to a Vote of Security Holders.
There have been no material changes to the procedures by which the shareholders may recommend nominees to the registrant’s board of trustees, where those changes were implemented after the registrant last provided disclosure in response to the requirements of Item 407(c)(2)(iv) of Regulation S-K (17 CFR 229.407) (as required by Item 22(b)(15) of Schedule 14A (17 CFR 240.14a-101)), or this Item.
Item 11. Controls and Procedures.
| (a) | As of a date within 90 days of the filing date of this Form N-CSR, the registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) (17 CFR 270.30a-3(c))) are effective, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)). |
| (b) | There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d)) that occurred during the registrant’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
Item 12. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.
Not applicable.
Item 13. Exhibits.
| (a)(1) | Code of ethics, or any amendment thereto, that is the subject of disclosure required by Item 2 is attached hereto. |
| (a)(2) | Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto. |
| (b) | Certifications pursuant to Rule 30a-2(b) under the 1940 Act and Section 906 of the Sarbanes-Oxley Act of 2002 are attached hereto. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| (Registrant) | ARK ETF Trust | |
| By (Signature and Title)* | /s/ Catherine D. Wood | |
| | Catherine D. Wood, Chief Executive Officer and Chief Investment Officer | |
| | (principal executive officer) | |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By (Signature and Title)* | /s/ Catherine D. Wood | |
| | Catherine D. Wood, Chief Executive Officer and Chief Investment Officer | |
| | (principal executive officer) | |
| By (Signature and Title)* | /s/ William C. Cox | |
| | William C. Cox, Treasurer and Chief Financial Officer | |
| | (principal financial officer) | |
* Print the name and title of each signing officer under his or her signature.
![[GRAPHIC MISSING]](https://capedge.com/proxy/N-CSR/0001144204-18-051987/logo_ark-etf.jpg){kind=logo}